WO2022251516A2 - Complexes à chélateurs acycliques et leur utilisation en radiothérapie ciblée de cancer - Google Patents
Complexes à chélateurs acycliques et leur utilisation en radiothérapie ciblée de cancer Download PDFInfo
- Publication number
- WO2022251516A2 WO2022251516A2 PCT/US2022/031157 US2022031157W WO2022251516A2 WO 2022251516 A2 WO2022251516 A2 WO 2022251516A2 US 2022031157 W US2022031157 W US 2022031157W WO 2022251516 A2 WO2022251516 A2 WO 2022251516A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- formula
- pharmaceutically acceptable
- solvate
- acceptable salt
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 58
- 201000011510 cancer Diseases 0.000 title claims abstract description 42
- 238000001959 radiotherapy Methods 0.000 title claims abstract description 9
- 239000002738 chelating agent Substances 0.000 title claims description 38
- 125000002015 acyclic group Chemical group 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 495
- 150000003839 salts Chemical class 0.000 claims abstract description 201
- 239000012453 solvate Substances 0.000 claims abstract description 193
- -1 such compounds Chemical class 0.000 claims abstract description 99
- 239000000203 mixture Substances 0.000 claims abstract description 49
- 239000000427 antigen Substances 0.000 claims abstract description 37
- 108091007433 antigens Proteins 0.000 claims abstract description 37
- 102000036639 antigens Human genes 0.000 claims abstract description 37
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 151
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 127
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 127
- 125000003118 aryl group Chemical group 0.000 claims description 115
- 125000000217 alkyl group Chemical group 0.000 claims description 79
- 125000004432 carbon atom Chemical group C* 0.000 claims description 71
- 125000000623 heterocyclic group Chemical group 0.000 claims description 68
- 230000008685 targeting Effects 0.000 claims description 66
- 125000001072 heteroaryl group Chemical group 0.000 claims description 56
- 238000000034 method Methods 0.000 claims description 55
- 239000012217 radiopharmaceutical Substances 0.000 claims description 53
- 229940127044 therapeutic radiopharmaceutical Drugs 0.000 claims description 53
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 49
- 239000012634 fragment Substances 0.000 claims description 49
- 125000003342 alkenyl group Chemical group 0.000 claims description 45
- 125000000304 alkynyl group Chemical group 0.000 claims description 45
- 125000001475 halogen functional group Chemical group 0.000 claims description 44
- 239000008194 pharmaceutical composition Substances 0.000 claims description 38
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 33
- 210000001519 tissue Anatomy 0.000 claims description 30
- 230000021615 conjugation Effects 0.000 claims description 29
- 229910005948 SO2Cl Inorganic materials 0.000 claims description 28
- 125000003700 epoxy group Chemical group 0.000 claims description 28
- 229910001868 water Inorganic materials 0.000 claims description 26
- 125000002947 alkylene group Chemical group 0.000 claims description 23
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 claims description 22
- 229950007906 codrituzumab Drugs 0.000 claims description 22
- 108010072257 fibroblast activation protein alpha Proteins 0.000 claims description 22
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 20
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 20
- 206010033128 Ovarian cancer Diseases 0.000 claims description 18
- 150000001413 amino acids Chemical class 0.000 claims description 15
- 229960003270 belimumab Drugs 0.000 claims description 15
- 229960004497 dinutuximab Drugs 0.000 claims description 15
- 239000003937 drug carrier Substances 0.000 claims description 15
- 201000007270 liver cancer Diseases 0.000 claims description 15
- 208000014018 liver neoplasm Diseases 0.000 claims description 15
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 15
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 14
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 14
- 125000000081 (C5-C8) cycloalkenyl group Chemical group 0.000 claims description 14
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 claims description 14
- 108010088751 Albumins Proteins 0.000 claims description 14
- 102000009027 Albumins Human genes 0.000 claims description 14
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 14
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 14
- GYHNNYVSQQEPJS-OIOBTWANSA-N Gallium-67 Chemical compound [67Ga] GYHNNYVSQQEPJS-OIOBTWANSA-N 0.000 claims description 14
- GYHNNYVSQQEPJS-YPZZEJLDSA-N Gallium-68 Chemical compound [68Ga] GYHNNYVSQQEPJS-YPZZEJLDSA-N 0.000 claims description 14
- XYVNHPYNSPGYLI-UUOKFMHZSA-N [(2r,3s,4r,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)-4-hydroxy-2-(phosphonooxymethyl)oxolan-3-yl] dihydrogen phosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H]1O XYVNHPYNSPGYLI-UUOKFMHZSA-N 0.000 claims description 14
- 108010081667 aflibercept Proteins 0.000 claims description 14
- 229960000548 alemtuzumab Drugs 0.000 claims description 14
- 229960003852 atezolizumab Drugs 0.000 claims description 14
- 229950002916 avelumab Drugs 0.000 claims description 14
- 229960000397 bevacizumab Drugs 0.000 claims description 14
- 229960003008 blinatumomab Drugs 0.000 claims description 14
- 229960000455 brentuximab vedotin Drugs 0.000 claims description 14
- 229940034605 capromab pendetide Drugs 0.000 claims description 14
- 229960000419 catumaxomab Drugs 0.000 claims description 14
- 229940121420 cemiplimab Drugs 0.000 claims description 14
- 229960005395 cetuximab Drugs 0.000 claims description 14
- 229950006647 cixutumumab Drugs 0.000 claims description 14
- 229960002204 daratumumab Drugs 0.000 claims description 14
- 229960001251 denosumab Drugs 0.000 claims description 14
- 229950009791 durvalumab Drugs 0.000 claims description 14
- 229960004137 elotuzumab Drugs 0.000 claims description 14
- 229950009569 etaracizumab Drugs 0.000 claims description 14
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 claims description 14
- 229950002026 girentuximab Drugs 0.000 claims description 14
- 229960001001 ibritumomab tiuxetan Drugs 0.000 claims description 14
- APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 claims description 14
- 229950004101 inotuzumab ozogamicin Drugs 0.000 claims description 14
- 229960005386 ipilimumab Drugs 0.000 claims description 14
- 229950007699 mogamulizumab Drugs 0.000 claims description 14
- 229950000720 moxetumomab pasudotox Drugs 0.000 claims description 14
- 229960000513 necitumumab Drugs 0.000 claims description 14
- 229950010203 nimotuzumab Drugs 0.000 claims description 14
- 229960003301 nivolumab Drugs 0.000 claims description 14
- 229960003347 obinutuzumab Drugs 0.000 claims description 14
- 229960002450 ofatumumab Drugs 0.000 claims description 14
- 229950008516 olaratumab Drugs 0.000 claims description 14
- 229960001972 panitumumab Drugs 0.000 claims description 14
- 229960002621 pembrolizumab Drugs 0.000 claims description 14
- 229960002087 pertuzumab Drugs 0.000 claims description 14
- 229960002633 ramucirumab Drugs 0.000 claims description 14
- 229960004641 rituximab Drugs 0.000 claims description 14
- 229960003323 siltuximab Drugs 0.000 claims description 14
- 229960005267 tositumomab Drugs 0.000 claims description 14
- 229960000575 trastuzumab Drugs 0.000 claims description 14
- 229960001612 trastuzumab emtansine Drugs 0.000 claims description 14
- 229960002760 ziv-aflibercept Drugs 0.000 claims description 14
- 229940123694 Bombesin receptor agonist Drugs 0.000 claims description 13
- 229940123051 Somatostatin receptor agonist Drugs 0.000 claims description 13
- 125000005647 linker group Chemical group 0.000 claims description 13
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 13
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 12
- 206010005003 Bladder cancer Diseases 0.000 claims description 11
- 206010006187 Breast cancer Diseases 0.000 claims description 11
- 208000026310 Breast neoplasm Diseases 0.000 claims description 11
- 206010060862 Prostate cancer Diseases 0.000 claims description 11
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 11
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 11
- 208000029742 colonic neoplasm Diseases 0.000 claims description 11
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 11
- 102000004506 Blood Proteins Human genes 0.000 claims description 9
- 108010017384 Blood Proteins Proteins 0.000 claims description 9
- 206010009944 Colon cancer Diseases 0.000 claims description 9
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 claims description 9
- 206010014733 Endometrial cancer Diseases 0.000 claims description 9
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 9
- 208000032612 Glial tumor Diseases 0.000 claims description 9
- 206010018338 Glioma Diseases 0.000 claims description 9
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 9
- 206010047741 Vulval cancer Diseases 0.000 claims description 9
- 230000001919 adrenal effect Effects 0.000 claims description 9
- 208000019065 cervical carcinoma Diseases 0.000 claims description 9
- 230000001054 cortical effect Effects 0.000 claims description 9
- 239000002552 dosage form Substances 0.000 claims description 9
- 201000003914 endometrial carcinoma Diseases 0.000 claims description 9
- 201000006585 gastric adenocarcinoma Diseases 0.000 claims description 9
- 230000001394 metastastic effect Effects 0.000 claims description 9
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 9
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 9
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 9
- 201000004916 vulva carcinoma Diseases 0.000 claims description 9
- 208000013013 vulvar carcinoma Diseases 0.000 claims description 9
- 238000007911 parenteral administration Methods 0.000 claims description 6
- 239000013598 vector Substances 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 206010029260 Neuroblastoma Diseases 0.000 claims description 5
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims description 5
- 208000009311 VIPoma Diseases 0.000 claims description 5
- 201000011519 neuroendocrine tumor Diseases 0.000 claims description 5
- 108091023037 Aptamer Proteins 0.000 claims description 4
- 108090001090 Lectins Proteins 0.000 claims description 4
- 102000004856 Lectins Human genes 0.000 claims description 4
- 108091034117 Oligonucleotide Proteins 0.000 claims description 4
- 102000015636 Oligopeptides Human genes 0.000 claims description 4
- 108010038807 Oligopeptides Proteins 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 108091008324 binding proteins Proteins 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 208000020475 growth hormone-producing pituitary gland neoplasm Diseases 0.000 claims description 4
- 239000002523 lectin Substances 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 206010052399 Neuroendocrine tumour Diseases 0.000 claims description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 3
- 208000016065 neuroendocrine neoplasm Diseases 0.000 claims description 3
- 208000010916 pituitary tumor Diseases 0.000 claims description 3
- 102000023732 binding proteins Human genes 0.000 claims 1
- 238000005516 engineering process Methods 0.000 abstract description 83
- 229910052770 Uranium Inorganic materials 0.000 abstract description 13
- JFALSRSLKYAFGM-UHFFFAOYSA-N uranium(0) Chemical compound [U] JFALSRSLKYAFGM-UHFFFAOYSA-N 0.000 abstract description 13
- 238000002560 therapeutic procedure Methods 0.000 abstract description 2
- 235000002639 sodium chloride Nutrition 0.000 description 144
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 81
- 239000000243 solution Substances 0.000 description 70
- 125000005289 uranyl group Chemical group 0.000 description 48
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 28
- 239000003446 ligand Substances 0.000 description 26
- 239000000725 suspension Substances 0.000 description 23
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 22
- 235000018102 proteins Nutrition 0.000 description 22
- 102000004169 proteins and genes Human genes 0.000 description 22
- 108090000623 proteins and genes Proteins 0.000 description 22
- 238000006243 chemical reaction Methods 0.000 description 21
- 239000000460 chlorine Substances 0.000 description 21
- 229910052739 hydrogen Inorganic materials 0.000 description 21
- 239000007787 solid Substances 0.000 description 21
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 20
- 102000010956 Glypican Human genes 0.000 description 20
- 108050001154 Glypican Proteins 0.000 description 20
- 108050007237 Glypican-3 Proteins 0.000 description 20
- 125000004093 cyano group Chemical group *C#N 0.000 description 20
- 239000001257 hydrogen Substances 0.000 description 20
- 102000005962 receptors Human genes 0.000 description 20
- 108020003175 receptors Proteins 0.000 description 20
- 239000000126 substance Substances 0.000 description 20
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 18
- 238000005160 1H NMR spectroscopy Methods 0.000 description 17
- 125000001424 substituent group Chemical group 0.000 description 17
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- 125000003710 aryl alkyl group Chemical group 0.000 description 13
- 238000010668 complexation reaction Methods 0.000 description 13
- 239000013078 crystal Substances 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- 238000004009 13C{1H}-NMR spectroscopy Methods 0.000 description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 12
- 229940024606 amino acid Drugs 0.000 description 12
- 235000001014 amino acid Nutrition 0.000 description 12
- 239000010949 copper Substances 0.000 description 12
- 239000002244 precipitate Substances 0.000 description 12
- 125000004429 atom Chemical group 0.000 description 11
- 239000000843 powder Substances 0.000 description 11
- 125000000539 amino acid group Chemical group 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 229910052799 carbon Inorganic materials 0.000 description 10
- 230000000295 complement effect Effects 0.000 description 10
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 10
- 238000010992 reflux Methods 0.000 description 10
- 229910002007 uranyl nitrate Inorganic materials 0.000 description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
- 125000000524 functional group Chemical group 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 235000019198 oils Nutrition 0.000 description 9
- 210000002381 plasma Anatomy 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 8
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 238000010168 coupling process Methods 0.000 description 8
- 238000005859 coupling reaction Methods 0.000 description 8
- 238000001914 filtration Methods 0.000 description 8
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 8
- 230000003287 optical effect Effects 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 8
- 238000004448 titration Methods 0.000 description 8
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 8
- 108010056088 Somatostatin Proteins 0.000 description 7
- 238000002441 X-ray diffraction Methods 0.000 description 7
- 150000001408 amides Chemical class 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 230000008878 coupling Effects 0.000 description 7
- 235000018417 cysteine Nutrition 0.000 description 7
- 229960002433 cysteine Drugs 0.000 description 7
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 6
- 102000005157 Somatostatin Human genes 0.000 description 6
- 239000007983 Tris buffer Substances 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- 150000007942 carboxylates Chemical class 0.000 description 6
- 238000012512 characterization method Methods 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 238000009792 diffusion process Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 6
- 125000005842 heteroatom Chemical group 0.000 description 6
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 229910017604 nitric acid Inorganic materials 0.000 description 6
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 238000002390 rotary evaporation Methods 0.000 description 6
- 239000012279 sodium borohydride Substances 0.000 description 6
- 229910000033 sodium borohydride Inorganic materials 0.000 description 6
- 229960000553 somatostatin Drugs 0.000 description 6
- 239000011550 stock solution Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- QXZBMSIDSOZZHK-DOPDSADYSA-N 31362-50-2 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CNC=N1 QXZBMSIDSOZZHK-DOPDSADYSA-N 0.000 description 5
- 108010051479 Bombesin Proteins 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 102100036519 Gastrin-releasing peptide Human genes 0.000 description 5
- 108050001286 Somatostatin Receptor Proteins 0.000 description 5
- 102000011096 Somatostatin receptor Human genes 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000000556 agonist Substances 0.000 description 5
- 125000003545 alkoxy group Chemical group 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 238000000921 elemental analysis Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 229910052736 halogen Inorganic materials 0.000 description 5
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 150000002678 macrocyclic compounds Chemical class 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 5
- 150000003573 thiols Chemical class 0.000 description 5
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 4
- 108010073466 Bombesin Receptors Proteins 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 4
- 101710151321 Melanostatin Proteins 0.000 description 4
- 229910002651 NO3 Inorganic materials 0.000 description 4
- 102400000064 Neuropeptide Y Human genes 0.000 description 4
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 4
- 102000008092 Norepinephrine Plasma Membrane Transport Proteins Human genes 0.000 description 4
- 108010049586 Norepinephrine Plasma Membrane Transport Proteins Proteins 0.000 description 4
- 108010016076 Octreotide Proteins 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000000611 antibody drug conjugate Substances 0.000 description 4
- 229940049595 antibody-drug conjugate Drugs 0.000 description 4
- 150000001540 azides Chemical class 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000012650 click reaction Methods 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- ZPWOOKQUDFIEIX-UHFFFAOYSA-N cyclooctyne Chemical compound C1CCCC#CCC1 ZPWOOKQUDFIEIX-UHFFFAOYSA-N 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 125000004475 heteroaralkyl group Chemical group 0.000 description 4
- 238000011065 in-situ storage Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- SQDFHQJTAWCFIB-UHFFFAOYSA-N n-methylidenehydroxylamine Chemical compound ON=C SQDFHQJTAWCFIB-UHFFFAOYSA-N 0.000 description 4
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 4
- 229960002700 octreotide Drugs 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 4
- PUDHBTGHUJUUFI-SCTWWAJVSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-p Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 PUDHBTGHUJUUFI-SCTWWAJVSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- 206010000599 Acromegaly Diseases 0.000 description 3
- ZUHQCDZJPTXVCU-UHFFFAOYSA-N C1#CCCC2=CC=CC=C2C2=CC=CC=C21 Chemical compound C1#CCCC2=CC=CC=C2C2=CC=CC=C21 ZUHQCDZJPTXVCU-UHFFFAOYSA-N 0.000 description 3
- 102000014914 Carrier Proteins Human genes 0.000 description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 3
- 125000004104 aryloxy group Chemical group 0.000 description 3
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 3
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229910052802 copper Inorganic materials 0.000 description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
- 238000001097 direct analysis in real time mass spectrometry Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 150000004677 hydrates Chemical class 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 125000001041 indolyl group Chemical group 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 108010021336 lanreotide Proteins 0.000 description 3
- 229960002437 lanreotide Drugs 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 102000014187 peptide receptors Human genes 0.000 description 3
- 108010011903 peptide receptors Proteins 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000005588 protonation Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- SWXOGPJRIDTIRL-DOUNNPEJSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s)-1-amino-3-(1h-indol-3-yl)-1-oxopropan-2-yl]-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-pent Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 SWXOGPJRIDTIRL-DOUNNPEJSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000269339 Bombina bombina Species 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 2
- 125000006519 CCH3 Chemical group 0.000 description 2
- RJXJOKUKUSWPFQ-UHFFFAOYSA-N COC(=O)C1=CC=CC(=N1)C=NC1CCCCC1 Chemical compound COC(=O)C1=CC=CC(=N1)C=NC1CCCCC1 RJXJOKUKUSWPFQ-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010007270 Carcinoid syndrome Diseases 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 102100039250 Essential MCU regulator, mitochondrial Human genes 0.000 description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108091006027 G proteins Proteins 0.000 description 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 2
- 102000030782 GTP binding Human genes 0.000 description 2
- 108091000058 GTP-Binding Proteins 0.000 description 2
- 102100039401 Gap junction beta-6 protein Human genes 0.000 description 2
- 102100039997 Gastric inhibitory polypeptide receptor Human genes 0.000 description 2
- 102000047481 Gastrin-releasing peptide receptors Human genes 0.000 description 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 2
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 102000004989 Hepsin Human genes 0.000 description 2
- 108090001101 Hepsin Proteins 0.000 description 2
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 2
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 2
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 description 2
- 101000813097 Homo sapiens Essential MCU regulator, mitochondrial Proteins 0.000 description 2
- 101000889125 Homo sapiens Gap junction beta-6 protein Proteins 0.000 description 2
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 description 2
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 101000638154 Homo sapiens Transmembrane protease serine 2 Proteins 0.000 description 2
- 238000006736 Huisgen cycloaddition reaction Methods 0.000 description 2
- HCUARRIEZVDMPT-UHFFFAOYSA-N Indole-2-carboxylic acid Chemical class C1=CC=C2NC(C(=O)O)=CC2=C1 HCUARRIEZVDMPT-UHFFFAOYSA-N 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- 241000283891 Kobus Species 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 108010008707 Mucin-1 Proteins 0.000 description 2
- 102100034256 Mucin-1 Human genes 0.000 description 2
- 108010008699 Mucin-4 Proteins 0.000 description 2
- 102100022693 Mucin-4 Human genes 0.000 description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 description 2
- 102100024028 Progonadoliberin-1 Human genes 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- 229910018162 SeO2 Inorganic materials 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 2
- 102100031989 Transmembrane protease serine 2 Human genes 0.000 description 2
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
- 108091008605 VEGF receptors Proteins 0.000 description 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 2
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 2
- 102400000015 Vasoactive intestinal peptide Human genes 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 125000005426 adeninyl group Chemical group N1=C(N=C2N=CNC2=C1N)* 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 150000001409 amidines Chemical class 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 125000005602 azabenzimidazolyl group Chemical group 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 235000013877 carbamide Nutrition 0.000 description 2
- 125000001589 carboacyl group Chemical group 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000009920 chelation Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 201000010897 colon adenocarcinoma Diseases 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- RYGMFSIKBFXOCR-IGMARMGPSA-N copper-64 Chemical compound [64Cu] RYGMFSIKBFXOCR-IGMARMGPSA-N 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 239000000032 diagnostic agent Substances 0.000 description 2
- 229940039227 diagnostic agent Drugs 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000000375 direct analysis in real time Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000000132 electrospray ionisation Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 150000002081 enamines Chemical class 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 102000006815 folate receptor Human genes 0.000 description 2
- 108020005243 folate receptor Proteins 0.000 description 2
- 229940013688 formic acid Drugs 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 229940006110 gallium-67 Drugs 0.000 description 2
- 108010036598 gastric inhibitory polypeptide receptor Proteins 0.000 description 2
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 2
- 150000002357 guanidines Chemical class 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 125000002632 imidazolidinyl group Chemical group 0.000 description 2
- 125000002636 imidazolinyl group Chemical group 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 2
- 150000003949 imides Chemical class 0.000 description 2
- 150000002466 imines Chemical class 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000000859 incretin Substances 0.000 description 2
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 229940055742 indium-111 Drugs 0.000 description 2
- 238000001095 inductively coupled plasma mass spectrometry Methods 0.000 description 2
- 229940030980 inova Drugs 0.000 description 2
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- QCQYVCMYGCHVMR-AAZUGDAUSA-N n-[(2r,3r,4s,5r)-4,5,6-trihydroxy-1-oxo-3-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexan-2-yl]acetamide Chemical compound CC(=O)N[C@@H](C=O)[C@H]([C@@H](O)[C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O QCQYVCMYGCHVMR-AAZUGDAUSA-N 0.000 description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 125000002524 organometallic group Chemical group 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 150000002923 oximes Chemical class 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- VMZMNAABQBOLAK-DBILLSOUSA-N pasireotide Chemical compound C([C@H]1C(=O)N2C[C@@H](C[C@H]2C(=O)N[C@H](C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@H](C(N[C@@H](CC=2C=CC(OCC=3C=CC=CC=3)=CC=2)C(=O)N1)=O)CCCCN)C=1C=CC=CC=1)OC(=O)NCCN)C1=CC=CC=C1 VMZMNAABQBOLAK-DBILLSOUSA-N 0.000 description 2
- 108700017947 pasireotide Proteins 0.000 description 2
- 229960005415 pasireotide Drugs 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000003918 potentiometric titration Methods 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 2
- JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000004763 sulfides Chemical class 0.000 description 2
- 150000003457 sulfones Chemical class 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 150000003462 sulfoxides Chemical class 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 101150047061 tag-72 gene Proteins 0.000 description 2
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000005208 trialkylammonium group Chemical group 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 229910052722 tritium Inorganic materials 0.000 description 2
- 238000002371 ultraviolet--visible spectrum Methods 0.000 description 2
- JFALSRSLKYAFGM-QQVBLGSISA-N uranium-230 Chemical compound [230U] JFALSRSLKYAFGM-QQVBLGSISA-N 0.000 description 2
- 102000009816 urokinase plasminogen activator receptor activity proteins Human genes 0.000 description 2
- 108040001269 urokinase plasminogen activator receptor activity proteins Proteins 0.000 description 2
- 108700029852 vapreotide Proteins 0.000 description 2
- 229960002730 vapreotide Drugs 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- AVRPFRMDMNDIDH-UHFFFAOYSA-N 1h-quinazolin-2-one Chemical class C1=CC=CC2=NC(O)=NC=C21 AVRPFRMDMNDIDH-UHFFFAOYSA-N 0.000 description 1
- AACILMLPSLEQMF-UHFFFAOYSA-N 2,2-dichloroethenyl 2-ethylsulfinylethyl methyl phosphate Chemical compound CCS(=O)CCOP(=O)(OC)OC=C(Cl)Cl AACILMLPSLEQMF-UHFFFAOYSA-N 0.000 description 1
- OXBLVCZKDOZZOJ-UHFFFAOYSA-N 2,3-Dihydrothiophene Chemical compound C1CC=CS1 OXBLVCZKDOZZOJ-UHFFFAOYSA-N 0.000 description 1
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- FJSHTWVDFAUNCO-UHFFFAOYSA-N 2-(4-iodophenyl)acetic acid Chemical class OC(=O)CC1=CC=C(I)C=C1 FJSHTWVDFAUNCO-UHFFFAOYSA-N 0.000 description 1
- WXUGKQUYLHLWGY-UHFFFAOYSA-N 2-[[2-[(8-hydroxyquinolin-2-yl)methylamino]ethylamino]methyl]quinolin-8-ol Chemical compound C1=CC=C(O)C2=NC(CNCCNCC3=CC=C4C=CC=C(C4=N3)O)=CC=C21 WXUGKQUYLHLWGY-UHFFFAOYSA-N 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- AQYNZOSCOWGGTP-UHFFFAOYSA-N 2-pyridin-2-ylsulfanylpyridine Chemical compound C=1C=CC=NC=1SC1=CC=CC=N1 AQYNZOSCOWGGTP-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- SJMRZGIIQIWIFS-UHFFFAOYSA-N 3-(4-iodophenyl)propanoic acid Chemical class OC(=O)CCC1=CC=C(I)C=C1 SJMRZGIIQIWIFS-UHFFFAOYSA-N 0.000 description 1
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 1
- OGOMLUBUDYFIOG-UHFFFAOYSA-N 4-(4-iodophenyl)butanoic acid Chemical class OC(=O)CCCC1=CC=C(I)C=C1 OGOMLUBUDYFIOG-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- KTIOSKUXBNFTFX-UHFFFAOYSA-N 4-oxo-4-(5,6,7,8-tetrahydronaphthalen-2-yl)butanoic acid Chemical class C1CCCC2=CC(C(=O)CCC(=O)O)=CC=C21 KTIOSKUXBNFTFX-UHFFFAOYSA-N 0.000 description 1
- CCZACPBJJXGQBC-UHFFFAOYSA-N 6-[[2-[(6-carboxypyridin-2-yl)methylamino]ethylamino]methyl]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC=CC(CNCCNCC=2N=C(C=CC=2)C(O)=O)=N1 CCZACPBJJXGQBC-UHFFFAOYSA-N 0.000 description 1
- APOZIAFCARLWHU-HOTGVXAUSA-N 6-[[[(1S,2S)-2-[(6-carboxypyridin-2-yl)methylamino]cyclohexyl]amino]methyl]pyridine-2-carboxylic acid Chemical compound OC(=O)c1cccc(CN[C@H]2CCCC[C@@H]2NCc2cccc(n2)C(O)=O)n1 APOZIAFCARLWHU-HOTGVXAUSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- SLBPIHCMXPQAIQ-UHFFFAOYSA-N 8-hydroxyquinoline-2-carbaldehyde Chemical compound C1=C(C=O)N=C2C(O)=CC=CC2=C1 SLBPIHCMXPQAIQ-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 102000008096 B7-H1 Antigen Human genes 0.000 description 1
- 108010074708 B7-H1 Antigen Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 102100028628 Bombesin receptor subtype-3 Human genes 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- 239000008000 CHES buffer Substances 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000010667 Carcinoma of liver and intrahepatic biliary tract Diseases 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102100030851 Cortistatin Human genes 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 238000005698 Diels-Alder reaction Methods 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000463291 Elga Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical group NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 1
- 210000000712 G cell Anatomy 0.000 description 1
- 102400000921 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000013382 Gelatinases Human genes 0.000 description 1
- 108010026132 Gelatinases Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 206010073069 Hepatic cancer Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000695054 Homo sapiens Bombesin receptor subtype-3 Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 239000007987 MES buffer Substances 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 238000006845 Michael addition reaction Methods 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N N,N′-Dicyclohexylcarbodiimide Substances C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- MKWKNSIESPFAQN-UHFFFAOYSA-N N-cyclohexyl-2-aminoethanesulfonic acid Chemical compound OS(=O)(=O)CCNC1CCCCC1 MKWKNSIESPFAQN-UHFFFAOYSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- GBVZWYMALZPRLP-VXKWHMMOSA-N OC1=C2N=C(CN[C@@H](CCCC3)[C@H]3NCC(C=CC3=CC=C4)=NC3=C4O)C=CC2=CC=C1 Chemical compound OC1=C2N=C(CN[C@@H](CCCC3)[C@H]3NCC(C=CC3=CC=C4)=NC3=C4O)C=CC2=CC=C1 GBVZWYMALZPRLP-VXKWHMMOSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 208000010067 Pituitary ACTH Hypersecretion Diseases 0.000 description 1
- 201000005746 Pituitary adenoma Diseases 0.000 description 1
- 206010061538 Pituitary tumour benign Diseases 0.000 description 1
- 208000020627 Pituitary-dependent Cushing syndrome Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 101100165188 Schizophyllum commune BBR1 gene Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102100029563 Somatostatin Human genes 0.000 description 1
- 229940127504 Somatostatin Receptor Agonists Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 102100032853 Sushi, nidogen and EGF-like domain-containing protein 1 Human genes 0.000 description 1
- 208000016191 TSH-secreting pituitary adenoma Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 1
- 150000001224 Uranium Chemical class 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical group ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 231100000230 acceptable toxicity Toxicity 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 125000005236 alkanoylamino group Chemical group 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000005262 alkoxyamine group Chemical group 0.000 description 1
- 125000000278 alkyl amino alkyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004947 alkyl aryl amino group Chemical group 0.000 description 1
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000010976 amide bond formation reaction Methods 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 125000003828 azulenyl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 125000004622 benzoxazinyl group Chemical group O1NC(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- JSMRMEYFZHIPJV-UHFFFAOYSA-N bicyclo[2.1.1]hexane Chemical compound C1C2CC1CC2 JSMRMEYFZHIPJV-UHFFFAOYSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- 125000002603 chloroethyl group Chemical group [H]C([*])([H])C([H])([H])Cl 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229910052681 coesite Inorganic materials 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000011970 concomitant therapy Methods 0.000 description 1
- 239000000562 conjugate Substances 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 229910052906 cristobalite Inorganic materials 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 150000001913 cyanates Chemical class 0.000 description 1
- 238000006352 cycloaddition reaction Methods 0.000 description 1
- 125000000000 cycloalkoxy group Chemical group 0.000 description 1
- 125000004367 cycloalkylaryl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- SSJXIUAHEKJCMH-UHFFFAOYSA-N cyclohexane-1,2-diamine Chemical compound NC1CCCCC1N SSJXIUAHEKJCMH-UHFFFAOYSA-N 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000058 cyclopentadienyl group Chemical group C1(=CC=CC1)* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 125000005433 dihydrobenzodioxinyl group Chemical group O1C(COC2=C1C=CC=C2)* 0.000 description 1
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 229940052760 dopamine agonists Drugs 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- ZSWFCLXCOIISFI-UHFFFAOYSA-N endo-cyclopentadiene Natural products C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 208000001991 endodermal sinus tumor Diseases 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 235000019439 ethyl acetate Nutrition 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000007897 gelcap Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000006359 hepatoblastoma Diseases 0.000 description 1
- 125000002192 heptalenyl group Chemical group 0.000 description 1
- 125000005549 heteroarylene group Chemical group 0.000 description 1
- 125000005844 heterocyclyloxy group Chemical group 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- 150000002429 hydrazines Chemical class 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 150000002443 hydroxylamines Chemical class 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 125000005945 imidazopyridyl group Chemical group 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 238000009616 inductively coupled plasma Methods 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 125000002462 isocyano group Chemical group *[N+]#[C-] 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000000654 isopropylidene group Chemical group C(C)(C)=* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- IQVRBWUUXZMOPW-PKNBQFBNSA-N istradefylline Chemical compound CN1C=2C(=O)N(CC)C(=O)N(CC)C=2N=C1\C=C\C1=CC=C(OC)C(OC)=C1 IQVRBWUUXZMOPW-PKNBQFBNSA-N 0.000 description 1
- 238000010983 kinetics study Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 201000002250 liver carcinoma Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- QCAWEPFNJXQPAN-UHFFFAOYSA-N methoxyfenozide Chemical compound COC1=CC=CC(C(=O)NN(C(=O)C=2C=C(C)C=C(C)C=2)C(C)(C)C)=C1C QCAWEPFNJXQPAN-UHFFFAOYSA-N 0.000 description 1
- DVIUNMLAPDJWHL-UHFFFAOYSA-N methyl 6-(hydroxymethyl)pyridine-2-carboxylate Chemical compound COC(=O)C1=CC=CC(CO)=N1 DVIUNMLAPDJWHL-UHFFFAOYSA-N 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940075566 naphthalene Drugs 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- UFWIBTONFRDIAS-UHFFFAOYSA-N naphthalene-acid Natural products C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 1
- 150000002790 naphthalenes Chemical class 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- CFODQUSMSYDHBS-UHFFFAOYSA-N octreotate Chemical compound O=C1NC(CC=2C=CC=CC=2)C(=O)NC(CC=2[C]3C=CC=CC3=NC=2)C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)NC(C(=O)NC(C(O)C)C(O)=O)CSSCC1NC(=O)C(N)CC1=CC=CC=C1 CFODQUSMSYDHBS-UHFFFAOYSA-N 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 201000003707 ovarian clear cell carcinoma Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229940116315 oxalic acid Drugs 0.000 description 1
- IVMHDOBGNQOUHO-UHFFFAOYSA-N oxathiane Chemical compound C1CCSOC1 IVMHDOBGNQOUHO-UHFFFAOYSA-N 0.000 description 1
- 229960003540 oxyquinoline Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000000863 peptide conjugate Substances 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 208000021310 pituitary gland adenoma Diseases 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920006393 polyether sulfone Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000006085 pyrrolopyridyl group Chemical group 0.000 description 1
- 238000010966 qNMR Methods 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 229940051022 radioimmunoconjugate Drugs 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 230000003439 radiotherapeutic effect Effects 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 229910052706 scandium Inorganic materials 0.000 description 1
- SIXSYDAISGFNSX-UHFFFAOYSA-N scandium atom Chemical compound [Sc] SIXSYDAISGFNSX-UHFFFAOYSA-N 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 238000011894 semi-preparative HPLC Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000004467 single crystal X-ray diffraction Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229910052682 stishovite Inorganic materials 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000005017 substituted alkenyl group Chemical group 0.000 description 1
- 125000005415 substituted alkoxy group Chemical group 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000004426 substituted alkynyl group Chemical group 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000005944 tetrahydroimidazopyridyl group Chemical group 0.000 description 1
- 125000005888 tetrahydroindolyl group Chemical group 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000004001 thioalkyl group Chemical group 0.000 description 1
- 150000003567 thiocyanates Chemical class 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229910021654 trace metal Inorganic materials 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 229910052905 tridymite Inorganic materials 0.000 description 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N urethane group Chemical group NC(=O)OCC JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 150000003673 urethanes Chemical class 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000002966 varnish Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
- C07D215/30—Metal salts; Chelates
Definitions
- a compound of Formula (I) is provided: or a pharmaceutically acceptable salt and/or solvate thereof, wherein Z 1 is R 5 , and Z 2 is R 6 ; or Z 1 and Z 2 taken together are a C 4 alkylene group optionally substituted by R 9 ; Z 3 is R 7 , and Z 4 is C(O); or Z 3 and Z 4 taken together with the carbon atoms to which they are bound are a 6-membered aryl ring optionally substituted by R 10 ; Z 5 is R 8 , and Z 6 is C(O); or Z 5 and Z 6 are taken together with the carbon atoms to which they are bound are a 6-membered aryl ring optionally substituted by R 11 ; R 1 , R 2 , R 3
- a compound of Formula (II) is provided or a pharmaceutically acceptable salt and/or solvate thereof, wherein M 1 is 230 U, 67 Ga, 68 Ga, 64 Cu, or 111 In, optionally where M 1 is 230 UO 2 2+ , 230 U 6+ , 67 Ga 3+ , 6 8 Ga 3+ , 64 Cu 2+ , or 111 In 3+ ; Z 1 is R 5 , and Z 2 is R 6 ; or Z 1 and Z 2 taken together are a C4 alkylene group optionally substituted by R 9 ; Z 3 is R 7 , and Z 4 is C(O); or Z 3 and Z 4 taken together with the carbon atoms to which they are bound are a 6-membered aryl ring optionally substituted by R 10 ; Z 5 is R 8 , and Z 6 is C(O); or Z 5 and Z 6 are taken together with the carbon atoms to which they are bound are a 6-membered aryl ring
- the present technology provides a compound (e.g., a “targeting compound”) useful in targeted radiotherapy of cancer and/or mammalian tissue overexpressing, e.g., an antigen or a receptor, where the compound is of Formula (III) or a pharmaceutically acceptable salt and/or solvate thereof, wherein M 1 is 230 UO 2 , 67 Ga, 68 Ga, 64 Cu, or 111 In, optionally where M 1 is 230 UO 2 2+ , 230 U 6+ , 67 Ga 3+ , 6 8 Ga 3+ , 64 Cu 2+ , or 111 In 3+ ; Z 1 is H or –L 5 –R 25 , and Z 2 is H or –L 6 –R 26 ; or Z 1 and Z 2 taken together are a C 4 alkylene group optionally substituted by R 9 ; Z 3 is H or –L 7 –R 27 , and Z 4 is C(O); or Z 3 and Z 4 taken together with the
- a modified antibody, modified antibody fragment, or modified binding peptide comprising a linkage arising from conjugation of a compound of Formula (I) or pharmaceutically acceptable salt and/or solvate thereof, with an antibody, antibody fragment, or binding peptide.
- a modified antibody, modified antibody fragment, or modified binding peptide is provided that includes a linkage arising from conjugation of a compound of Formula (II) or a pharmaceutically acceptable salt and/or solvate thereof, with an antibody, antibody fragment, or binding peptide.
- the antibody includes Codrituzumab (GC33), belimumab, Mogamulizumab, Blinatumomab, Ibritumomab tiuxetan, Obinutuzumab, Ofatumumab, Rituximab, Inotuzumab ozogamicin, Moxetumomab pasudotox, Brentuximab vedotin, Daratumumab, Ipilimumab, Cetuximab, Necitumumab, Panitumumab, Dinutuximab, Pertuzumab, Trastuzumab, Trastuzumab emtansine, Siltuximab, Cemiplimab, Nivolumab, Pembrolizum
- the antibody fragment includes an antigen-binding fragment of Codrituzumab (GC33), belimumab, Mogamulizumab, Blinatumomab, Ibritumomab tiuxetan, Obinutuzumab, Ofatumumab, Rituximab, Inotuzumab ozogamicin, Moxetumomab pasudotox, Brentuximab vedotin, Daratumumab, Ipilimumab, Cetuximab, Necitumumab, Panitumumab, Dinutuximab, Pertuzumab, Trastuzumab, Trastuzumab emtansine, Siltuximab, Cemiplimab, Nivolumab, Pembrolizumab, Olaratumab, Atezolizumab, Avelumab, Durvalu
- the binding peptide includes a prostate specific membrane antigen (“PSMA”) binding peptide, a somatostatin receptor agonist, a bombesin receptor agonist, a seprase binding compound, or a binding fragment thereof.
- PSMA prostate specific membrane antigen
- the present technology also provides compositions (e.g., pharmaceutical compositions) and medicaments comprising any of one of the embodiments of the compounds of Formulas (I), (II), or (III) (or a pharmaceutically acceptable salt and/or solvate thereof) disclosed herein and a pharmaceutically acceptable carrier or one or more excipients or fillers.
- compositions e.g., pharmaceutical compositions
- medicaments comprising any of one of the embodiments of the therapeutic radiopharmaceutical agents comprising chelators (e.g., compounds of Formula (I)) and radionuclides disclosed herein and a pharmaceutically acceptable carrier or one or more excipients or fillers.
- compositions e.g., pharmaceutical compositions
- medicaments comprising any of one of the embodiments of the modified antibody, modified antibody fragment, or modified binding peptide of the present technology disclosed herein and a pharmaceutically acceptable carrier or one or more excipients or fillers.
- a method of treating a subject includes administering a targeting compound of the present technology to the subject or administering a modified antibody, modified antibody fragment, or modified binding peptide of the present technology to the subject.
- the subject suffers from cancer and/or mammalian tissue overexpressing, e.g., an antigen or a receptor.
- a compound is provided that includes a first domain having a blood- protein binding moiety with low specific affinity for the blood-protein, a second domain having a tumor targeting moiety with high affinity for a tumor antigen, and a third domain having a chelator.
- FIGs.1A-1H show X-ray crystal structures of the [UO 2 (L)] complexes.
- FIGs.1A and 1B show X-ray crystal structures of [UO 2 (dedpa)] (FIG.1A, top view; FIG.1B, side view).
- FIGs.1C and 1D show X-ray crystal structures of [UO 2 (CHXdedpa)] (FIG.1C, top view; FIG. 1D, side view).
- FIGs.1E and 1F show X-ray crystal structures of [UO 2 (hox)] (FIG.1E, top view; FIG.1F, side view).
- FIGs.1G and 1H show X-ray crystal structures of [UO 2 (CHXhox)](NO 3 ) (FIG.1G, top view; FIG.1H, side view). Thermal ellipsoids are drawn at the 50% probability level. Counterions, outer-sphere solvent molecules, and hydrogen atoms bound to carbon atoms are omitted for clarity. For [UO 2 (CHXdedpa)], only one of the two independent molecules present in the asymmetric unit is shown.
- FIGs.2A and 2B show the kinetic stability of [UO 2 (L)] complexes ([UO 2 (dedpa)], [UO 2 (CHXdedpa)], [UO 2 (hox)], and [UO 2 (CHXhox)], respectively) in 0.1 M TRIS buffer (pH 7.4, 37 °C) containing 2000 eq. HAP (FIG.2A) or human plasma (FIG.2B) over 14 d as measured by HPLC.
- FIGs.3A-3D show the ex vivo biodistribution profiles of [UO 2 (NO 3 )] ⁇ 6H 2 O (FIG.3A), [UO 2 (dedpa)] (FIG.3B), [UO 2 (CHXdedpa)] (FIG.3C), and [UO 2 (hox)] (FIG.3D) at 30 min, 2 h and 24 h.
- FIGs.3E-3F show comparison of the uranium content in the tibia (FIG.3E) and lung (FIG.3F) for the data shown in FIGs.3A-3D.
- an R group is defined to include hydrogen or H, it also includes deuterium and tritium.
- Compounds comprising radioisotopes such as tritium, C 14 , P 32 and S 35 are thus within the scope of the present technology. Procedures for inserting such labels into the compounds of the present technology will be readily apparent to those skilled in the art based on the disclosure herein.
- substituted refers to an organic group as defined below (e.g., an alkyl group) in which one or more bonds to a hydrogen atom contained therein are replaced by a bond to non-hydrogen or non-carbon atoms.
- Substituted groups also include groups in which one or more bonds to a carbon(s) or hydrogen(s) atom are replaced by one or more bonds, including double or triple bonds, to a heteroatom.
- a substituted group is substituted with one or more substituents, unless otherwise specified.
- a substituted group is substituted with 1, 2, 3, 4, 5, or 6 substituents.
- substituent groups include: halogens (i.e., F, Cl, Br, and I); hydroxyls; alkoxy, alkenoxy, aryloxy, aralkyloxy, heterocyclyl, heterocyclylalkyl, heterocyclyloxy, and heterocyclylalkoxy groups; carbonyls (oxo); carboxylates; esters; urethanes; oximes; hydroxylamines; alkoxyamines; aralkoxyamines; thiols; sulfides; sulfoxides; sulfones; sulfonyls; pentafluorosulfanyl (i.e., SF 5 ), sulfonamides; amines; N-oxides; hydrazines; hydrazides; hydrazones; azides; amides; ureas; amidines; guanidines; enamines; imides; isocyanates; isothi
- Substituted ring groups such as substituted cycloalkyl, aryl, heterocyclyl and heteroaryl groups also include rings and ring systems in which a bond to a hydrogen atom is replaced with a bond to a carbon atom. Therefore, substituted cycloalkyl, aryl, heterocyclyl and heteroaryl groups may also be substituted with substituted or unsubstituted alkyl, alkenyl, and alkynyl groups as defined below.
- C m -C n such as C 1 -C 12 , C 1 -C 8 , or C 1 -C 6 when used before a group refers to that group containing m to n carbon atoms.
- Alkyl groups include straight chain and branched chain alkyl groups having from 1 to 12 carbon atoms, and typically from 1 to 10 carbons or, in some embodiments, from 1 to 8, 1 to 6, or 1 to 4 carbon atoms.
- straight chain alkyl groups include groups such as methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, n-heptyl, and n-octyl groups.
- branched alkyl groups include, but are not limited to, isopropyl, iso-butyl, sec-butyl, tert-butyl, neopentyl, isopentyl, and 2,2-dimethylpropyl groups.
- Alkyl groups may be substituted or unsubstituted.
- substituted alkyl groups may be substituted one or more times with substituents such as those listed above, and include without limitation haloalkyl (e.g., trifluoromethyl), hydroxyalkyl, thioalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkoxyalkyl, carboxyalkyl, and the like.
- Cycloalkyl groups include mono-, bi- or tricyclic alkyl groups having from 3 to 12 carbon atoms in the ring(s), or, in some embodiments, 3 to 10, 3 to 8, or 3 to 4, 5, or 6 carbon atoms.
- Exemplary monocyclic cycloalkyl groups include, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl groups.
- the cycloalkyl group has 3 to 8 ring members, whereas in other embodiments the number of ring carbon atoms range from 3 to 5, 3 to 6, or 3 to 7.
- Bi- and tricyclic ring systems include both bridged cycloalkyl groups and fused rings, such as, but not limited to, bicyclo[2.1.1]hexane, adamantyl, decalinyl, and the like.
- Cycloalkyl groups may be substituted or unsubstituted. Substituted cycloalkyl groups may be substituted one or more times with, non-hydrogen and non-carbon groups as defined above. However, substituted cycloalkyl groups also include rings that are substituted with straight or branched chain alkyl groups as defined above. Representative substituted cycloalkyl groups may be mono-substituted or substituted more than once, such as, but not limited to, 2,2-, 2,3-, 2,4- 2,5- or 2,6-disubstituted cyclohexyl groups, which may be substituted with substituents such as those listed above.
- Cycloalkylalkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to a cycloalkyl group as defined above.
- cycloalkylalkyl groups have from 4 to 16 carbon atoms, 4 to 12 carbon atoms, and typically 4 to 10 carbon atoms.
- Cycloalkylalkyl groups may be substituted or unsubstituted. Substituted cycloalkylalkyl groups may be substituted at the alkyl, the cycloalkyl or both the alkyl and cycloalkyl portions of the group.
- Alkenyl groups include straight and branched chain alkyl groups as defined above, except that at least one double bond exists between two carbon atoms. Alkenyl groups have from 2 to 12 carbon atoms, and typically from 2 to 10 carbons or, in some embodiments, from 2 to 8, 2 to 6, or 2 to 4 carbon atoms. In some embodiments, the alkenyl group has one, two, or three carbon-carbon double bonds.
- Alkenyl groups may be substituted or unsubstituted.
- Representative substituted alkenyl groups may be mono-substituted or substituted more than once, such as, but not limited to, mono-, di- or tri-substituted with substituents such as those listed above.
- Cycloalkenyl groups include cycloalkyl groups as defined above, having at least one double bond between two carbon atoms.
- Cycloalkenyl groups may be substituted or unsubstituted. In some embodiments the cycloalkenyl group may have one, two or three double bonds but does not include aromatic compounds. Cycloalkenyl groups have from 4 to 14 carbon atoms, or, in some embodiments, 5 to 14 carbon atoms, 5 to 10 carbon atoms, or even 5, 6, 7, or 8 carbon atoms. Examples of cycloalkenyl groups include cyclohexenyl, cyclopentenyl, cyclohexadienyl, cyclobutadienyl, and cyclopentadienyl.
- Cycloalkenylalkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of the alkyl group is replaced with a bond to a cycloalkenyl group as defined above. Cycloalkenylalkyl groups may be substituted or unsubstituted. Substituted cycloalkenylalkyl groups may be substituted at the alkyl, the cycloalkenyl or both the alkyl and cycloalkenyl portions of the group. Representative substituted cycloalkenylalkyl groups may be substituted one or more times with substituents such as those listed above.
- Alkynyl groups include straight and branched chain alkyl groups as defined above, except that at least one triple bond exists between two carbon atoms.
- Alkynyl groups have from 2 to 12 carbon atoms, and typically from 2 to 10 carbons or, in some embodiments, from 2 to 8, 2 to 6, or 2 to 4 carbon atoms.
- the alkynyl group has one, two, or three carbon-carbon triple bonds. Examples include, but are not limited to – C ⁇ CH, -C ⁇ CCH 3 , -CH 2 C ⁇ CCH 3 , -C ⁇ CCH 2 CH(CH 2 CH 3 ) 2 , among others.
- Alkynyl groups may be substituted or unsubstituted.
- Aryl groups are cyclic aromatic hydrocarbons that do not contain heteroatoms.
- Aryl groups herein include monocyclic, bicyclic and tricyclic ring systems.
- aryl groups include, but are not limited to, phenyl, azulenyl, heptalenyl, biphenyl, fluorenyl, phenanthrenyl, anthracenyl, indenyl, indanyl, pentalenyl, and naphthyl groups.
- aryl groups contain 6-14 carbons, and in others from 6 to 12 or even 6-10 carbon atoms in the ring portions of the groups.
- the aryl groups are phenyl or naphthyl.
- Aryl groups may be substituted or unsubstituted.
- aryl groups includes groups containing fused rings, such as fused aromatic-aliphatic ring systems (e.g., indanyl, tetrahydronaphthyl, and the like). Representative substituted aryl groups may be mono- substituted or substituted more than once.
- monosubstituted aryl groups include, but are not limited to, 2-, 3-, 4-, 5-, or 6-substituted phenyl or naphthyl groups, which may be substituted with substituents such as those listed above.
- Aralkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to an aryl group as defined above.
- aralkyl groups contain 7 to 16 carbon atoms, 7 to 14 carbon atoms, or 7 to 10 carbon atoms.
- Aralkyl groups may be substituted or unsubstituted.
- Substituted aralkyl groups may be substituted at the alkyl, the aryl or both the alkyl and aryl portions of the group.
- Representative aralkyl groups include but are not limited to benzyl and phenethyl groups and fused (cycloalkylaryl)alkyl groups such as 4-indanylethyl.
- Representative substituted aralkyl groups may be substituted one or more times with substituents such as those listed above.
- Heterocyclyl groups include aromatic (also referred to as heteroaryl) and non-aromatic ring compounds containing 3 or more ring members, of which one or more is a heteroatom such as, but not limited to, N, O, and S.
- the heterocyclyl group contains 1, 2, 3 or 4 heteroatoms.
- heterocyclyl groups include mono-, bi- and tricyclic rings having 3 to 16 ring members, whereas other such groups have 3 to 6, 3 to 10, 3 to 12, or 3 to 14 ring members.
- Heterocyclyl groups encompass aromatic, partially unsaturated and saturated ring systems, such as, for example, imidazolyl, imidazolinyl and imidazolidinyl groups.
- heterocyclyl group includes fused ring species including those comprising fused aromatic and non-aromatic groups, such as, for example, benzotriazolyl, 2,3- dihydrobenzo[1,4]dioxinyl, and benzo[1,3]dioxolyl.
- the phrase also includes bridged polycyclic ring systems containing a heteroatom such as, but not limited to, quinuclidyl. Heterocyclyl groups may be substituted or unsubstituted.
- Heterocyclyl groups include, but are not limited to, aziridinyl, azetidinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, thiazolidinyl, tetrahydrothiophenyl, tetrahydrofuranyl, dioxolyl, furanyl, thiophenyl, pyrrolyl, pyrrolinyl, imidazolyl, imidazolinyl, pyrazolyl, pyrazolinyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiazolyl, thiazolinyl, isothiazolyl, thiadiazolyl, oxadiazolyl, piperidyl, piperazinyl, morpholinyl, thiomorpholinyl, tetrahydropyranyl, tetrahydrothiopyranyl,
- substituted heterocyclyl groups may be mono-substituted or substituted more than once, such as, but not limited to, pyridyl or morpholinyl groups, which are 2-, 3-, 4-, 5-, or 6-substituted, or disubstituted with various substituents such as those listed above.
- Heteroaryl groups are aromatic ring compounds containing 5 or more ring members, of which, one or more is a heteroatom such as, but not limited to, N, O, and S.
- Heteroaryl groups include, but are not limited to, groups such as pyrrolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiophenyl, benzothiophenyl, furanyl, benzofuranyl, indolyl, azaindolyl (pyrrolopyridinyl), indazolyl, benzimidazolyl, imidazopyridinyl (azabenzimidazolyl), pyrazolopyridinyl, triazolopyridinyl, benzotriazolyl, benzoxazolyl, benzothiazolyl, benzothiadiazolyl, imidazopyridinyl, isoxazolopyridinyl, thianaphthyl, purinyl,
- Heteroaryl groups include fused ring compounds in which all rings are aromatic such as indolyl groups and include fused ring compounds in which only one of the rings is aromatic, such as 2,3-dihydro indolyl groups. Heteroaryl groups may be substituted or unsubstituted. Thus, the phrase “heteroaryl groups” includes fused ring compounds as well as includes heteroaryl groups that have other groups bonded to one of the ring members, such as alkyl groups. Representative substituted heteroaryl groups may be substituted one or more times with various substituents such as those listed above.
- Heterocyclylalkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to a heterocyclyl group as defined above. Heterocyclylalkyl groups may be substituted or unsubstituted. Substituted heterocyclylalkyl groups may be substituted at the alkyl, the heterocyclyl or both the alkyl and heterocyclyl portions of the group.
- heterocyclyl alkyl groups include, but are not limited to, morpholin-4-yl-ethyl, furan-2-yl-methyl, imidazol-4-yl-methyl, pyridin-3-yl-methyl, tetrahydrofuran-2-yl-ethyl, and indol-2-yl-propyl.
- Representative substituted heterocyclylalkyl groups may be substituted one or more times with substituents such as those listed above.
- Heteroaralkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to a heteroaryl group as defined above. Heteroaralkyl groups may be substituted or unsubstituted.
- Substituted heteroaralkyl groups may be substituted at the alkyl, the heteroaryl or both the alkyl and heteroaryl portions of the group.
- Representative substituted heteroaralkyl groups may be substituted one or more times with substituents such as those listed above.
- Groups described herein having two or more points of attachment i.e., divalent, trivalent, or polyvalent
- divalent alkyl groups are alkylene groups
- divalent aryl groups are arylene groups
- divalent heteroaryl groups are divalent heteroarylene groups, and so forth.
- Substituted groups having a single point of attachment to the compound of the present technology are not referred to using the “ene” designation.
- chloroethyl is not referred to herein as chloroethylene.
- Such groups may further be substituted or unsubstituted.
- Alkoxy groups are hydroxyl groups (-OH) in which the bond to the hydrogen atom is replaced by a bond to a carbon atom of a substituted or unsubstituted alkyl group as defined above.
- Examples of linear alkoxy groups include but are not limited to methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, and the like.
- Examples of branched alkoxy groups include but are not limited to isopropoxy, sec-butoxy, tert-butoxy, isopentoxy, isohexoxy, and the like.
- Examples of cycloalkoxy groups include but are not limited to cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, and the like.
- Alkoxy groups may be substituted or unsubstituted. Representative substituted alkoxy groups may be substituted one or more times with substituents such as those listed above.
- alkanoyl and alkanoyloxy can refer, respectively, to – C(O)–alkyl and –O–C(O)–alkyl groups, where in some embodiments the alkanoyl or alkanoyloxy groups each contain 2–5 carbon atoms.
- aryloyl and aryloyloxy respectively refer to –C(O)–aryl and –O–C(O)–aryl groups.
- aryloxy and arylalkoxy refer to, respectively, a substituted or unsubstituted aryl group bonded to an oxygen atom and a substituted or unsubstituted aralkyl group bonded to the oxygen atom at the alkyl. Examples include but are not limited to phenoxy, naphthyloxy, and benzyloxy. Representative substituted aryloxy and arylalkoxy groups may be substituted one or more times with substituents such as those listed above. [0040]
- carboxylic acid as used herein refers to a compound with a –C(O)OH group.
- carboxylate refers to a –C(O)O – group.
- a “protected carboxylate” refers to a –C(O)O-G where G is a carboxylate protecting group.
- Carboxylate protecting groups are well known to one of ordinary skill in the art. An extensive list of protecting groups for the carboxylate group functionality may be found in Protective Groups in Organic Synthesis, Greene, T.W.; Wuts, P. G. M., John Wiley & Sons, New York, NY, (3rd Edition, 1999) which can be added or removed using the procedures set forth therein and which is hereby incorporated by reference in its entirety and for any and all purposes as if fully set forth herein.
- esters refers to –COOR 70 groups.
- R 70 is a substituted or unsubstituted alkyl, cycloalkyl, alkenyl, alkynyl, aryl, aralkyl, heterocyclylalkyl or heterocyclyl group as defined herein.
- amide (or “amido”) includes C- and N-amide groups, i.e., -C(O)NR 71 R 72 , and –NR 71 C(O)R 72 groups, respectively.
- R 71 and R 72 are independently hydrogen, or a substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heterocyclylalkyl or heterocyclyl group as defined herein.
- Amido groups therefore include but are not limited to carbamoyl groups (-C(O)NH 2 ) and formamide groups (-NHC(O)H).
- the amide is –NR 71 C(O)-(C 1-5 alkyl) and the group is termed "carbonylamino,” and in others the amide is –NHC(O)-alkyl and the group is termed "alkanoylamino.”
- the term “nitrile” or “cyano” as used herein refers to the –CN group.
- Urethane groups include N- and O-urethane groups, i.e., -NR 73 C(O)OR 74 and -OC(O)NR 73 R 74 groups, respectively.
- R 73 and R 74 are independently a substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heterocyclylalkyl, or heterocyclyl group as defined herein.
- R 73 may also be H.
- amine or “amino” as used herein refers to –NR 75 R 76 groups, wherein R 75 and R 76 are independently hydrogen, or a substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heterocyclylalkyl or heterocyclyl group as defined herein.
- the amine is alkylamino, dialkylamino, arylamino, or alkylarylamino. In other embodiments, the amine is NH 2 , methylamino, dimethylamino, ethylamino, diethylamino, propylamino, isopropylamino, phenylamino, or benzylamino.
- sulfonamido includes S- and N-sulfonamide groups, i.e., -SO 2 NR 78 R 79 and –NR 78 SO 2 R 79 groups, respectively.
- R 78 and R 79 are independently hydrogen, or a substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heterocyclylalkyl, or heterocyclyl group as defined herein.
- Sulfonamido groups therefore include but are not limited to sulfamoyl groups (-SO 2 NH 2 ).
- the sulfonamido is –NHSO 2 -alkyl and is referred to as the "alkylsulfonylamino" group.
- thiol refers to —SH groups
- sulfides include —SR 80 groups
- sulfoxides include —S(O)R 81 groups
- sulfones include -SO 2 R 82 groups
- sulfonyls include —SO 2 OR 83 .
- R 80 , R 81 , R 82 , and R 83 are each independently a substituted or unsubstituted alkyl, cycloalkyl, alkenyl, alkynyl, aryl aralkyl, heterocyclyl or heterocyclylalkyl group as defined herein.
- the sulfide is an alkylthio group, -S-alkyl.
- urea refers to –NR 84 -C(O)-NR 85 R 86 groups.
- R 84 , R 85 , and R 86 groups are independently hydrogen, or a substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heterocyclyl, or heterocyclylalkyl group as defined herein.
- amidine refers to –C(NR 87 )NR 88 R 89 and –NR 87 C(NR 88 )R 89 , wherein R 87 , R 88 , and R 89 are each independently hydrogen, or a substituted or unsubstituted alkyl, cycloalkyl, alkenyl, alkynyl, aryl aralkyl, heterocyclyl or heterocyclylalkyl group as defined herein.
- guanidine refers to –NR 90 C(NR 91 )NR 92 R 93 , wherein R 90 , R 91 , R 92 and R 93 are each independently hydrogen, or a substituted or unsubstituted alkyl, cycloalkyl, alkenyl, alkynyl, aryl aralkyl, heterocyclyl or heterocyclylalkyl group as defined herein.
- halogen or “halo” as used herein refers to bromine, chlorine, fluorine, or iodine.
- the halogen is fluorine. In other embodiments, the halogen is chlorine or bromine.
- hydroxyl as used herein can refer to –OH or its ionized form, –O – .
- the term “imide” refers to –C(O)NR 98 C(O)R 99 , wherein R 98 and R 99 are each independently hydrogen, or a substituted or unsubstituted alkyl, cycloalkyl, alkenyl, alkynyl, aryl aralkyl, heterocyclyl or heterocyclylalkyl group as defined herein.
- the term “imine” refers to –CR 100 (NR 101 ) and –N(CR 100 R 101 ) groups, wherein R 100 and R 101 are each independently hydrogen or a substituted or unsubstituted alkyl, cycloalkyl, alkenyl, alkynyl, aryl aralkyl, heterocyclyl or heterocyclylalkyl group as defined herein, with the proviso that R 100 and R 101 are not both simultaneously hydrogen.
- nitro as used herein refers to an –NO 2 group.
- the term “trifluoromethyl” as used herein refers to –CF 3 .
- trifluoromethoxy refers to –OCF 3 .
- zido refers to –N 3 .
- trifluoromethyldiazirido refers to [0062]
- isocyano refers to –NC.
- isothiocyano refers to –NCS.
- salts of compounds described herein are within the scope of the present technology and include acid or base addition salts which retain the desired pharmacological activity and is not biologically undesirable (e.g., the salt is not unduly toxic, allergenic, or irritating, and is bioavailable).
- pharmaceutically acceptable salts can be formed with inorganic acids (such as hydrochloric acid, hydroboric acid, nitric acid, sulfuric acid, and phosphoric acid), organic acids (e.g., alginate, formic acid, acetic acid, benzoic acid, gluconic acid, fumaric acid, oxalic acid, tartaric acid, lactic acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, naphthalene sulfonic acid, and p-toluenesulfonic acid) or acidic amino acids (such as aspartic acid and glutamic acid).
- inorganic acids such as hydrochloric acid, hydroboric acid, nitric acid, sulfuric acid, and phosphoric acid
- organic acids e.g., alginate, formic acid, acetic acid, benzoic acid, gluconic acid, fumaric acid, ox
- the compound of the present technology when it has an acidic group, such as for example, a carboxylic acid group, it can form salts with metals, such as alkali and earth alkali metals (e.g., Na + , Li + , K + , Ca 2+ , Mg 2+ , Zn 2+ ), ammonia or organic amines (e.g. dicyclohexylamine, trimethylamine, triethylamine, pyridine, picoline, ethanolamine, diethanolamine, triethanolamine) or basic amino acids (e.g., arginine, lysine and ornithine).
- alkali and earth alkali metals e.g., Na + , Li + , K + , Ca 2+ , Mg 2+ , Zn 2+
- ammonia or organic amines e.g. dicyclohexylamine, trimethylamine, triethylamine, pyridine, picoline, ethanolamine,
- Such salts can be prepared in situ during isolation and purification of the compounds or by separately reacting the purified compound in its free base or free acid form with a suitable acid or base, respectively, and isolating the salt thus formed.
- Those of skill in the art will appreciate that compounds of the present technology may exhibit the phenomena of tautomerism, conformational isomerism, geometric isomerism and/or stereoisomerism.
- Tautomers refers to isomeric forms of a compound that are in equilibrium with each other. The presence and concentrations of the isomeric forms will depend on the environment the compound is found in and may be different depending upon, for example, whether the compound is a solid or is in an organic or aqueous solution.
- quinazolinones may exhibit the following isomeric forms, which are referred to as tautomers of each other: .
- guanidines may exhibit the following isomeric forms in protic organic solution, also referred to as tautomers of each other: .
- Stereoisomers of compounds also known as optical isomers
- compounds used in the present technology include enriched or resolved optical isomers at any or all asymmetric atoms as are apparent from the depictions. Both racemic and diastereomeric mixtures, as well as the individual optical isomers can be isolated or synthesized so as to be substantially free of their enantiomeric or diastereomeric partners, and these stereoisomers are all within the scope of the present technology.
- the compounds of the present technology may exist as solvates, especially hydrates. Hydrates may form during manufacture of the compounds or compositions comprising the compounds, or hydrates may form over time due to the hygroscopic nature of the compounds.
- Alpha-emitting radionuclides are of much higher energy, and thus substantially more potent, than beta-emitting radionuclides. Additionally, the radionuclide 230 U possesses a 20.8-day half-life, and thus can be suitable for use with the long biological circulation time of antibody-based targeting vectors.
- At least one of R 1 , R 2 , R 3 , R 4 , Z 1 , Z 2 , Z 3 , or Z 5 in Formula (I) is not H. In any embodiment herein, it may be that one of R 1 , R 2 , R 3 , R 4 , Z 1 , Z 2 , Z 3 , or Z 5 in Formula (I) is not H and the remainder are H.
- the compounds of the invention may have one or more chiral centers.
- certain uncomplexed form of Formula (I) can be complexed with a radionuclide, such as an alpha-emitting radionuclide, at room temperature (e.g., 18-30°C, or about or no more than 20°C, 25°C, or 30°C) at high radiochemical yields, e.g., at least or greater than 90%, 95%, 97%, or 98%.
- a radionuclide such as an alpha-emitting radionuclide
- a compound of Formula (II) is provided or a pharmaceutically acceptable salt and/or solvate thereof, wherein M 1 is 230 U, 67 Ga, 68 Ga, 64 Cu, or 111 In; Z 1 is R 5 , and Z 2 is R 6 ; or Z 1 and Z 2 taken together are a C 4 alkylene group optionally substituted by R 9 ; Z 3 is R 7 , and Z 4 is C(O); or Z 3 and Z 4 taken together with the carbon atoms to which they are bound are a 6-membered aryl ring optionally substituted by R 10 ; Z 5 is R 8 , and Z 6 is C(O); or Z 5 and Z 6 are taken together with the carbon atoms to which they are bound are a 6-membered aryl ring optionally substituted by R 11 ; R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 are each independently H, OH, NH
- M 1 is uranium-230 ( 230 UO 2 2+ or 230 U 6+ ), gallium-67 ( 67 Ga 3+ ), gallium-68 ( 68 Ga 3+ ), copper-64 ( 64 Cu 2+ ), or Indium-111 ( 111 In 3+ ).
- the present technology provides a compound (e.g., a “targeting compound”) useful in targeted radiotherapies, for example, targeted radiotherapy of cancer and/or mammalian tissue overexpressing e.g., an antigen or a receptor, where the compound is of Formula (III) or a pharmaceutically acceptable salt and/or solvate thereof, wherein M 1 is 230 U, 67 Ga, 68 Ga, 64 Cu, or 111 In; Z 1 is H or –L 5 –R 25 , and Z 2 is H or –L 6 –R 26 ; or Z 1 and Z 2 taken together are a C4 alkylene group optionally substituted by R 9 ; Z 3 is H or –L 7 –R 27 , and Z 4 is C(O); or Z 3 and Z 4 taken together with the carbon atoms to which they are bound are a 6-membered aryl ring optionally substituted by R 10 ; Z 5 is H or –L 8 –R 28 , and
- M 1 is uranium-230 ( 230 UO 2 2+ or 230 U 6+ ), gallium-67 ( 67 Ga 3+ ), gallium-68 ( 68 Ga 3+ ), copper-64 ( 64 Cu 2+ ), or Indium-111 ( 111 In 3+ ).
- Representative R 21 , R 25 , R 26 , R 27 , and R 28 groups include those antibodies listed in Table A as well as antigen-binding fragments of such antibodies and any equivalent embodiments, as would be known to those of ordinary skill in the art. Belimumab 7138501 1 g 2 Also designated Ch14.18.
- the binding peptide comprises a prostate specific membrane antigen (“PSMA”) binding peptide, a somatostatin receptor agonist, a bombesin receptor agonist, a seprase binding compound, or a binding fragment thereof.
- PSMA prostate specific membrane antigen
- PSMA binding peptides include, but are not limited to, those according to the following structure where nn is 0, 1, or 2, and P 1 , P 2 , and P 3 are each independently H, methyl, benzyl, 4- methoxybenzyl, or tert-butyl. In any embodiment herein, it may be that each of P 1 , P 2 , and P 3 are H.
- Somatostatin illustrated in Scheme A, is a peptide hormone that regulates the endocrine system and affects neurotransmission and cell proliferation via interaction with G protein-coupled somatostatin receptors and inhibition of the release of numerous secondary hormones. Somatostatin has two active forms produced by alternative cleavage of a single preproprotein.
- somatostatin receptors There are five known somatostatin receptors, all being G protein-coupled seven transmembrane receptors: SST1 (SSTR1); SST2 (SSTR2); SST3 (SSTR3); SST4 (SSTR4); and SST5 (SSTR5).
- Exemplary somatostatin receptor agonists include somatostatin itself, lanreotide, octreotate, octreotide, pasireotide, and vapreotide.
- Octreotide is an octapeptide that mimics natural somatostatin but has a significantly longer half-life in vivo.
- Octreotide is used for the treatment of growth hormone producing tumors (acromegaly and gigantism), when surgery is contraindicated, pituitary tumors that secrete thyroid stimulating hormone (thyrotropinoma), diarrhea and flushing episodes associated with carcinoid syndrome, and diarrhea in people with vasoactive intestinal peptide-secreting tumors (VIPomas).
- Lanreotide is used in the management of acromegaly and symptoms caused by neuroendocrine tumors, most notably carcinoid syndrome.
- Pasireotide is a somatostatin analog with an increased affinity to SSTR5 compared to other somatostatin agonists and is approved for treatment of Cushing's disease and acromegaly. Vapreotide is is used in the treatment of esophageal variceal bleeding in patients with cirrhotic liver disease and AIDS-related diarrhea.
- Bombesin is a peptide originally isolated from the skin of the European fire-bellied toad (Bombina bombina). In addition to stimulating gastrin release from G cells, bombesin activates at least three different G-protein-coupled receptors: BBR1, BBR2, and BBR3, where such activity includes agonism of such receptors in the brain.
- Bombesin is also a tumor marker for small cell carcinoma of lung, gastric cancer, pancreatic cancer, and neuroblastoma.
- Bombesin receptor agonists include, but are not limited to, BBR-1 agonists, BBR-2 agonists, and BBR-3 agonists.
- Seprase or Fibroblast Activation Protein (FAP) is an integral membrane serine peptidase. In addition to gelatinase activity, seprase has a dual function in tumour progression. Seprase promotes cell invasiveness towards the ECM and also supports tumour growth and proliferation. Seprase binding compounds include seprase inhibitors.
- Glypican-3 is a cell-surface glycoprotein consisting of heparan sulfate glycosaminoglycan chains and an inner protein core. Glypican-3 immunostaining has utility for differentiating hepatocellular carcinoma (HCC) (see, e.g., Filmus J, Capurro M (2004). "Glypican-3 and alphafetoprotein as diagnostic tests for hepatocellular carcinoma”. Molecular Diagnosis.8 (4): 207–212) and dysplastic changes in cirrhotic livers; HCC stains with glypican 3, while liver with dysplastic changes and/or cirrhotic changes does not.
- HCC hepatocellular carcinoma
- GPC3 protein expression has been found in HCC, not in normal liver and cholangiocarcinoma. GPC3 is also expressed to a lesser degree in melanoma, ovarian clear-cell carcinomas, yolk sac tumors, neuroblastoma, hepatoblastoma, Wilms' tumor cells, and other tumors. GPC3 is a promising therapeutic target for treating liver cancer (see, e.g., Ishiguro T, Sugimoto M, Kinoshita Y, Miyazaki Y, Nakano K, Tsunoda H, et al. "Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer". Cancer Research.68 (23): 9832–9838).
- a modified antibody, modified antibody fragment, or modified binding peptide comprising a linkage arising from conjugation of a compound of Formula (I) or pharmaceutically acceptable salt and/or solvate thereof, with an antibody, antibody fragment, or binding peptide.
- a modified antibody, modified antibody fragment, or modified binding peptide is provided that includes a linkage arising from conjugation of a compound of Formula (II) or a pharmaceutically acceptable salt and/or solvate thereof, with an antibody, antibody fragment, or binding peptide.
- the antibody includes belimumab, Mogamulizumab, Blinatumomab, Ibritumomab tiuxetan, Obinutuzumab, Ofatumumab, Rituximab, Inotuzumab ozogamicin, Moxetumomab pasudotox, Brentuximab vedotin, Daratumumab, Ipilimumab, Cetuximab, Necitumumab, Panitumumab, Dinutuximab, Pertuzumab, Trastuzumab, Trastuzumab emtansine, Siltuximab, Cemiplimab, Nivolumab, Pembrolizumab, Olaratumab, Atezolizumab, Avelumab, Durvalumab, Capromab pendetide, Elotuzumab,
- the antibody fragment includes an antigen-binding fragment of belimumab, Mogamulizumab, Blinatumomab, Ibritumomab tiuxetan, Obinutuzumab, Ofatumumab, Rituximab, Inotuzumab ozogamicin, Moxetumomab pasudotox, Brentuximab vedotin, Daratumumab, Ipilimumab, Cetuximab, Necitumumab, Panitumumab, Dinutuximab, Pertuzumab, Trastuzumab, Trastuzumab emtansine, Siltuximab, Cemiplimab, Nivolumab, Pembrolizumab, Olaratumab, Atezolizumab, Avelumab, Durvalumab, Capromab pendet
- the binding peptide includes a prostate specific membrane antigen (“PSMA”) binding peptide, a somatostatin receptor agonist, a bombesin receptor agonist, a seprase binding compound, or a binding fragment thereof.
- PSMA prostate specific membrane antigen
- the binding peptide includes Codrituzumab (GC33) or a binding fragment thereof.
- modified antibody, modified antibody fragment, or modified binding peptide of the present technology it may be that the linkage arises from conjugation of the compound with the antibody, antibody fragment, or binding peptide; and wherein the compound is a compound of Formula (I) (e.g., a compound of Formula (I-A), (I-B1), (I-B2), (I- C1), (I-C2), (I-D1), (I-D2), or (I-D3)), or pharmaceutically acceptable salt and/or solvate thereof.
- a compound of Formula (I) e.g., a compound of Formula (I-A), (I-B1), (I-B2), (I- C1), (I-C2), (I-D1), (I-D2), or (I-D3)
- pharmaceutically acceptable salt and/or solvate thereof e.g., a compound of Formula (I-A), (I-B1), (I-B2), (I- C1), (I-C2), (I
- a modified antibody, modified antibody fragment, or modified binding peptide of the present technology it may be that the linkage arises from conjugation of the compound with the antibody, antibody fragment, or binding peptide; and wherein the compound is a compound of Formula (II) (e.g., a compound of Formula (II-A), (II-B1), (II-B2), (II-C1), (II-C2), (II-D1), (II-D2), or (II-D3)), or pharmaceutically acceptable salt and/or solvate thereof.
- a compound of Formula (II) e.g., a compound of Formula (II-A), (II-B1), (II-B2), (II-C1), (II-C2), (II-D1), (II-D2), or (II-D3)
- pharmaceutically acceptable salt and/or solvate thereof e.g., a compound of Formula (II-A), (II-B
- the structures include compounds of Formula (I-A) (e.g., compounds of Formula (I-A*) or (I-A**)); a therapeutic radiopharmaceutical agent comprising a compound of Formula (I-A) or pharmaceutically acceptable salt and/or solvate thereof and a radionuclide; a modified antibody, modified antibody fragment, or modified binding peptide comprising a linkage arising from conjugation of a compound of Formula (I-A) or pharmaceutically acceptable salt and/or solvate thereof, with an antibody, antibody fragment, or binding peptide; compounds of Formula (II-A) (e.g., compounds of Formula (II-A*) or (II- A**)); a modified antibody, modified antibody fragment, or modified binding peptide comprising a linkage arising from conjugation of a compound of Formula (II-A) or pharmaceutically acceptable salt and/or solvate thereof, with an antibody, antibody fragment, or binding peptide; and targeting compounds of
- a compound of Formula (II-A) is a compound of Formula (II- A*) or Formula (II-A**)
- a compound of Formula (III-A) is a compound of Formula (III- A*) or Formula (III-A**)
- a therapeutic radiopharmaceutical agent described herein comprises a compound and a radionuclide, where the compound is , or a pharmaceutically acceptable salt and/or solvate thereof.
- a compound of Formula (II-A) is or a pharmaceutically acceptable salt and/or solvate thereof, wherein M 1 is a radionuclide.
- M 1 is a radionuclide.
- a modified antibody, modified antibody fragment, or modified binding peptide of the present technology it may be that the modified antibody, modified antibody fragment, or modified binding peptide comprises a moiety having the following structure wherein one of the hydrogens is being substituted by a linkage or a pharmaceutically acceptable salt and/or solvate thereof.
- Targeting compounds of Formula (III-A) may be prepared by a process that includes reacting a compound of Formula (I-A) or (II-A) with R 21 -R 1a , where Table B provides representative examples (where n is independently at each occurrence 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10).
- R 21 may be conjugated to moiety R 41 by reaction of complementary chemical functional groups R 1a and R 1 (e.g., represented by –X 1 -W 1 in Table B) to form linker L 1 (e.g., represented by –X 1 -LL 1 in Table B).
- R 1a and R 1 e.g., represented by –X 1 -W 1 in Table B
- linker L 1 e.g., represented by –X 1 -LL 1 in Table B.
- R 21 -R 1a may include a modified target amino acid residue within a protein (e.g., a target amino acid residue described herein such as one of the representative antibodies disclosed in Table A or an antigen-binding fragment thereof; a PSMA binding peptide, a somatostatin receptor agonist, a bombesin receptor agonist, a seprase binding compound, or a binding fragment of any one thereof; or an antibody codrituzumab (GC33), or a binding fragment of any one thereof).
- a target amino acid residue described herein such as one of the representative antibodies disclosed in Table A or an antigen-binding fragment thereof
- a PSMA binding peptide e.g., a somatostatin receptor agonist, a bombesin receptor agonist, a seprase binding compound, or a binding fragment of any one thereof
- GC33 antibody codrituzumab
- R 1a may include a reactive chemical functional moiety, non-limiting examples of which are disclosed in the Table B, where R 1 (e.g., represented by –X 1 -W 1 in Table B) may be selected to selectively react with R 1a in order to provide L 1 (e.g., represented by –X 1 -LL 1 in Table B) of Formula (III-A).
- R 1 e.g., represented by –X 1 -W 1 in Table B
- L 1 e.g., represented by –X 1 -LL 1 in Table B
- the structures include compounds of Formula (I-B1) (e.g., compounds of Formula (I-B1*) or Formula (I-B1**)); a therapeutic radiopharmaceutical agent comprising a compound of Formula (I-B1) or pharmaceutically acceptable salt and/or solvate thereof and a radionuclide; a modified antibody, modified antibody fragment, or modified binding peptide comprising a linkage arising from conjugation of a compound of Formula (I-B1) or pharmaceutically acceptable salt and/or solvate thereof, with an antibody, antibody fragment, or binding peptide; compounds of Formula (II-B1) (e.g., compounds of Formula (II-B1*) or Formula (II-B1**)), a modified antibody, modified antibody fragment, or modified binding peptide comprising a linkage arising from conjugation of a compound of Formula (II-B1) or pharmaceutically acceptable salt and/or solvate thereof, with an antibody, antibody fragment, or binding peptide;
- a compound of Formula (I-B1) is a compound of Formula (I- B1*) or Formula (I-B1**) [0106] In some embodiments, a compound of Formula (II-B1) is a compound of Formula (II- B1*) or Formula (II-B1**) [0107] In some embodiments, a compound of Formula (III-B1) is a compound of Formula (III- B1*) or Formula (III-B1**) [0108] Targeting compounds of Formula (III-B1) may be prepared by a process that includes reacting a compound of Formula (I-B1) with R 21 -R 1a , where Table B provides representative examples (where n is independently at each occurrence 1, 2, 3, 4, 5,
- R 21 may be conjugated to moiety R 42a by reaction of complementary chemical functional groups R 1 (e.g., represented by –X 1 -W 1 in Table B) and R 1a to form linker L 1 (e.g., represented by –X 1 - LL 1 in Table B).
- R 1 complementary chemical functional groups
- R 1a e.g., represented by –X 1 -W 1 in Table B
- linker L 1 e.g., represented by –X 1 - LL 1 in Table B.
- R 21 -R 1a may include a modified target amino acid residue within a protein (e.g., one of the representative antibodies disclosed in Table A or an antigen-binding fragment thereof; a PSMA binding peptide, a somatostatin receptor agonist, a bombesin receptor agonist, a seprase binding compound, or a binding fragment of any one thereof; or an antibody codrituzumab (GC33), or a binding fragment of any one thereof).
- a protein e.g., one of the representative antibodies disclosed in Table A or an antigen-binding fragment thereof; a PSMA binding peptide, a somatostatin receptor agonist, a bombesin receptor agonist, a seprase binding compound, or a binding fragment of any one thereof; or an antibody codrituzumab (GC33), or a binding fragment of any one thereof).
- R 1 may include a reactive chemical functional moiety, non-limiting examples of which are disclosed in the Table B, where R 1 (e.g., represented by –X 1 -W 1 in Table B) may be selected to selectively react with R 1a in order to provide L 1 (e.g., represented by –X 1 -LL 1 in Table B) of Formula (III-B1).
- R 1 e.g., represented by –X 1 -W 1 in Table B
- L 1 e.g., represented by –X 1 -LL 1 in Table B
- the structures include compounds of Formula (I- B2) (e.g., compounds of Formula (I-B2*) or Formula (I-B2**)); a therapeutic radiopharmaceutical agent comprising a compound of Formula (I-B2) or pharmaceutically acceptable salt and/or solvate thereof and a radionuclide; a modified antibody, modified antibody fragment, or modified binding peptide comprising a linkage arising from conjugation of a compound of Formula (I-B2) or pharmaceutically acceptable salt and/or solvate thereof, with an antibody, antibody fragment, or binding peptide; compounds of Formula (II-B2) (e.g., compounds of Formula (II-B2*) or Formula (II-B2**)); a modified antibody, modified antibody fragment, or modified binding peptide comprising a linkage arising from conjugation of a compound of Formula (II-B2) or pharmaceutically acceptable salt and/or solvate thereof, with an antibody, antibody fragment, or binding peptide
- a compound of Formula (I-B2) is a compound of Formula (I- B2*) or Formula (I-B2**)
- a compound of Formula (II-B2) is a compound of Formula (II- B2*) or Formula (II-B2**)
- a compound of Formula (III-B2) is a compound of Formula (III- B2*) or Formula (III-B2**)
- Targeting compounds of Formula (III-B2) may be prepared by a process that includes reacting a compound of Formula (I-B2) with R 21 -R 1a , where Table B provides representative examples (where n is independently at each occurrence 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10).
- R 21 may be conjugated to moiety R 42b by reaction of complementary chemical functional groups R 10 (e.g., represented by –X 1 -W 1 in Table B) and R 1a to form linker L 1 (e.g., represented by –X 1 - LL 1 in Table B).
- R 21 -R 1a may include a modified target amino acid residue within a protein (e.g., one of the representative antibodies disclosed in Table A or an antigen-binding fragment thereof; a PSMA binding peptide, a somatostatin receptor agonist, a bombesin receptor agonist, a seprase binding compound, or a binding fragment of any one thereof; or an antibody codrituzumab (GC33), or a binding fragment of any one thereof).
- a protein e.g., one of the representative antibodies disclosed in Table A or an antigen-binding fragment thereof; a PSMA binding peptide, a somatostatin receptor agonist, a bombesin receptor agonist, a seprase binding compound, or a binding fragment of any one thereof; or an antibody codrituzumab (GC33), or a binding fragment of any one thereof).
- R 10 may include a reactive chemical functional moiety, non-limiting examples of which are disclosed in the Table B, where R 10 (e.g., represented by –X 1 -W 1 in Table B) may be selected to selectively react with R 1a in order to provide L 1 (e.g., represented by –X 1 -LL 1 in Table B) of Formula (III-B2).
- a therapeutic radiopharmaceutical agent described herein comprises a compound and a radionuclide, where the compound is or a pharmaceutically acceptable salt and/or solvate thereof.
- a compound of Formula (II-B1) or (II-B2) is or a pharmaceutically acceptable salt and/or solvate thereof, wherein M 1 is a radionuclide.
- M 1 is a radionuclide.
- a modified antibody, modified antibody fragment, or modified binding peptide of the present technology it may be that the modified antibody, modified antibody fragment, or modified binding peptide comprises a moiety having the following structure wherein one of the hydrogens is being substituted by a linkage or a pharmaceutically acceptable salt and/or solvate thereof.
- modified antibody, modified antibody fragment, or modified binding peptide of the present technology it may be that the modified antibody, modified antibody fragment, or modified binding peptide comprises a moiety having the following structure wherein one of the hydrogens is being substituted by a linkage or a pharmaceutically acceptable salt and/or solvate thereof.
- the structures include compounds of Formula (I-C1); a therapeutic radiopharmaceutical agent comprising a compound of Formula (I-C1) or pharmaceutically acceptable salt and/or solvate thereof and a radionuclide; a modified antibody, modified antibody fragment, or modified binding peptide comprising a linkage arising from conjugation of a compound of Formula (I-C1) or pharmaceutically acceptable salt and/or solvate thereof, with an antibody, antibody fragment, or binding peptide; compounds of Formula (II- C1); a modified antibody, modified antibody fragment, or modified binding peptide comprising a linkage arising from conjugation of a compound of Formula (II-C1) or pharmaceutically acceptable salt and/or solvate thereof, with an antibody, antibody fragment, or binding peptide; and targeting compounds of Formula (III-C1).
- a therapeutic radiopharmaceutical agent comprising a compound of Formula (I-C1) or pharmaceutically acceptable salt and/or solvate thereof and a radionuclide
- Targeting compounds of Formula (III-C1) may be prepared by a process that includes reacting a compound of Formula (I-C1) or (II-C1) with R 21 -R 1a , where Table B provides representative examples (where n is independently at each occurrence 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10).
- R 21 may be conjugated to macrocycle R 43a by reaction of complementary chemical functional groups R 1 (e.g., represented by –X 1 -W 1 in Table B) and R 1a to form linker L 1 (e.g., represented by –X 1 -LL 1 in Table B).
- R 1 complementary chemical functional groups
- R 1a e.g., represented by –X 1 -W 1 in Table B
- linker L 1 e.g., represented by –X 1 -LL 1 in Table B.
- R 21 -R 1a may include a modified target amino acid residue within a protein (e.g., one of the representative antibodies disclosed in Table A or an antigen-binding fragment thereof; a PSMA binding peptide, a somatostatin receptor agonist, a bombesin receptor agonist, a seprase binding compound, or a binding fragment of any one thereof; or an antibody codrituzumab (GC33), or a binding fragment of any one thereof).
- a protein e.g., one of the representative antibodies disclosed in Table A or an antigen-binding fragment thereof; a PSMA binding peptide, a somatostatin receptor agonist, a bombesin receptor agonist, a seprase binding compound, or a binding fragment of any one thereof; or an antibody codrituzumab (GC33), or a binding fragment of any one thereof).
- R 1 may include a reactive chemical functional moiety, non-limiting examples of which are disclosed in the Table B, where R 1 (e.g., represented by –X 1 -W 1 in Table B) may be selected to selectively react with R 1a in order to provide L 1 (e.g., represented by –X 1 -LL 1 in Table B) of Formula (III- C1) [0120]
- the structures include compounds of Formula (I-C2); a therapeutic radiopharmaceutical agent comprising a compound of Formula (I-C2) or pharmaceutically acceptable salt and/or solvate thereof and a radionuclide; a modified antibody, modified antibody fragment, or modified binding peptide comprising a linkage arising from conjugation of a compound of Formula (I-C2) or pharmaceutically acceptable salt and/or solvate thereof, with an antibody, antibody fragment, or binding peptide; compounds of Formula (II- C2); a modified antibody, modified antibody fragment, or modified binding peptide comprising a linkage
- Targeting compounds of Formula (III-C2) may be prepared by a process that includes reacting a compound of Formula (I-C2) or (II-C2) with R 25 -R 5a , where Table C provides representative examples (where n is independently at each occurrence 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10). As such, R 25 may be conjugated to macrocycle R 43b by reaction of complementary chemical functional groups R 5 and R 5a to form linker L 5 .
- R 25 -R 5a may include a modified target amino acid residue within a protein (e.g., one of the representative antibodies disclosed in Table A or an antigen-binding fragment thereof; a PSMA binding peptide, a somatostatin receptor agonist, a bombesin receptor agonist, a seprase binding compound, or a binding fragment of any one thereof; or an antibody codrituzumab (GC33), or a binding fragment of any one thereof).
- R 5 may include a reactive chemical functional moiety, non- limiting examples of which are disclosed in the Table C, where R 5 may be selected to selectively react with R 5a in order to provide L 5 of Formula (III-C2).
- a therapeutic radiopharmaceutical agent described herein comprises a compound and a radionuclide, where the compound is or a pharmaceutically acceptable salt and/or solvate thereof.
- a compound of Formula (II-C1) or (II-C2) is or a pharmaceutically acceptable salt and/or solvate thereof, wherein M 1 is a radionuclide.
- modified antibody, modified antibody fragment, or modified binding peptide of the present technology it may be that the modified antibody, modified antibody fragment, or modified binding peptide comprises a moiety having the following structure wherein one of the hydrogens is being substituted by a linkage or a pharmaceutically acceptable salt and/or solvate thereof.
- modified antibody, modified antibody fragment, or modified binding peptide comprises a moiety having the following structure wherein one of the hydrogens is being substituted by a linkage or a pharmaceutically acceptable salt and/or solvate thereof.
- the structures include compounds of Formula (I-D1); a therapeutic radiopharmaceutical agent comprising a compound of Formula (I-D1) or pharmaceutically acceptable salt and/or solvate thereof and a radionuclide; a modified antibody, modified antibody fragment, or modified binding peptide comprising a linkage arising from conjugation of a compound of Formula (I-D1) or pharmaceutically acceptable salt and/or solvate thereof, with an antibody, antibody fragment, or binding peptide; compounds of Formula (II- D1); a modified antibody, modified antibody fragment, or modified binding peptide comprising a linkage arising from conjugation of a compound of Formula (II-D1) or pharmaceutically acceptable salt and/or solvate thereof, with an antibody, antibody fragment, or binding peptide; and targeting compounds of Formula (III-D1).
- a therapeutic radiopharmaceutical agent comprising a compound of Formula (I-D1) or pharmaceutically acceptable salt and/or solvate thereof and a radionuclide
- Targeting compounds of Formula (III-D1) may be prepared by a process that includes reacting a compound of Formula (I-D1) or (II-D1) with R 21 -R 1a , where Table B provides representative examples (where n is independently at each occurrence 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10).
- R 21 may be conjugated to macrocycle R 44a by reaction of complementary chemical functional groups R 1 (e.g., represented by –X 1 -W 1 in Table B) and R 1a to form linker L 1 (e.g., represented by –X 1 -LL 1 in Table B).
- R 1 complementary chemical functional groups
- R 1a e.g., represented by –X 1 -W 1 in Table B
- linker L 1 e.g., represented by –X 1 -LL 1 in Table B.
- R 21 -R 1a may include a modified target amino acid residue within a protein (e.g., one of the representative antibodies disclosed in Table A or an antigen-binding fragment thereof; a PSMA binding peptide, a somatostatin receptor agonist, a bombesin receptor agonist, a seprase binding compound, or a binding fragment of any one thereof; or an antibody codrituzumab (GC33), or a binding fragment of any one thereof).
- a protein e.g., one of the representative antibodies disclosed in Table A or an antigen-binding fragment thereof; a PSMA binding peptide, a somatostatin receptor agonist, a bombesin receptor agonist, a seprase binding compound, or a binding fragment of any one thereof; or an antibody codrituzumab (GC33), or a binding fragment of any one thereof).
- R 1 may include a reactive chemical functional moiety, non-limiting examples of which are disclosed in the Table B, where R 1 (e.g., represented by –X 1 -W 1 in Table B) may be selected to selectively react with R 1a in order to provide L 1 (e.g., represented by –X 1 -LL 1 in Table B) of Formula (III- D1).
- R 1 e.g., represented by –X 1 -W 1 in Table B
- L 1 e.g., represented by –X 1 -LL 1 in Table B
- the structures include compounds of Formula (I-D2); a therapeutic radiopharmaceutical agent comprising a compound of Formula (I-D2) or pharmaceutically acceptable salt and/or solvate thereof and a radionuclide; a modified antibody, modified antibody fragment, or modified binding peptide comprising a linkage arising from conjugation of a compound of Formula (I-D2) or pharmaceutically acceptable salt and/or solvate thereof, with an antibody, antibody fragment, or binding peptide; compounds of Formula (II- D2); a modified antibody, modified antibody fragment, or modified binding peptide comprising a linkage arising from conjugation of a compound of Formula (II-D2) or pharmaceutically acceptable salt and/or solvate thereof, with an antibody, antibody fragment, or binding peptide; and targeting compounds of Formula (III-D2).
- a therapeutic radiopharmaceutical agent comprising a compound of Formula (I-D2) or pharmaceutically acceptable salt and/or solvate thereof and a radionuclide
- Targeting compounds of Formula (III-D2) may be prepared by a process that includes reacting a compound of Formula (I-D2) or (II-D2) with R 21 -R 1a , where Table B provides representative examples (where n is independently at each occurrence 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10).
- R 21 may be conjugated to macrocycle R 44b by reaction of complementary chemical functional groups R 10 (e.g., represented by –X 1 -W 1 in Table B) and R 1a to form linker L 1 (e.g., represented by –X 1 -LL 1 in Table B).
- R 10 complementary chemical functional groups
- R 1a linker L 1 (e.g., represented by –X 1 -LL 1 in Table B).
- R 21 -R 1a may include a modified target amino acid residue within a protein (e.g., one of the representative antibodies disclosed in Table A or an antigen-binding fragment thereof; a PSMA binding peptide, a somatostatin receptor agonist, a bombesin receptor agonist, a seprase binding compound, or a binding fragment of any one thereof; or an antibody codrituzumab (GC33), or a binding fragment of any one thereof).
- a protein e.g., one of the representative antibodies disclosed in Table A or an antigen-binding fragment thereof; a PSMA binding peptide, a somatostatin receptor agonist, a bombesin receptor agonist, a seprase binding compound, or a binding fragment of any one thereof; or an antibody codrituzumab (GC33), or a binding fragment of any one thereof).
- R 10 may include a reactive chemical functional moiety, non-limiting examples of which are disclosed in the Table B, where R 10 (e.g., represented by –X 1 -W 1 in Table B) may be selected to selectively react with R 1a in order to provide L 1 (e.g., represented by –X 1 -LL 1 in Table B) of Formula (III-D2).
- R 10 e.g., represented by –X 1 -W 1 in Table B
- L 1 e.g., represented by –X 1 -LL 1 in Table B
- the structures include compounds of Formula (I-D3); a therapeutic radiopharmaceutical agent comprising a compound of Formula (I-D3) or pharmaceutically acceptable salt and/or solvate thereof and a radionuclide; a modified antibody, modified antibody fragment, or modified binding peptide comprising a linkage arising from conjugation of a compound of Formula (I-D3) or pharmaceutically acceptable salt and/or solvate thereof, with an antibody, antibody fragment, or binding peptide; compounds of Formula (II- D3); a modified antibody, modified antibody fragment, or modified binding peptide comprising a linkage arising from conjugation of a compound of Formula (II-D3) or pharmaceutically acceptable salt and/or solvate thereof, with an antibody, antibody fragment, or binding peptide; and targeting compounds of Formula (III-D3).
- a therapeutic radiopharmaceutical agent comprising a compound of Formula (I-D3) or pharmaceutically acceptable salt and/or solvate thereof and a radionuclide
- Targeting compounds of Formula (III-D3) may be prepared by a process that includes reacting a compound of Formula (I-D3) or (II-D3) with R 25 -R 5a , where Table C provides representative examples (where n is independently at each occurrence 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10). As such, R 25 may be conjugated to macrocycle R 44c by reaction of complementary chemical functional groups R 5 and R 5a to form linker L 5 .
- R 25 -R 5a may include a modified target amino acid residue within a protein (e.g., one of the representative antibodies disclosed in Table A or an antigen-binding fragment thereof; a PSMA binding peptide, a somatostatin receptor agonist, a bombesin receptor agonist, a seprase binding compound, or a binding fragment of any one thereof; or an antibody codrituzumab (GC33), or a binding fragment of any one thereof).
- R 5 may include a reactive chemical functional moiety, non-limiting examples of which are disclosed in the Table C, where R 5 may be selected to selectively react with R 5a in order to provide L 5 of Formula (III-D3).
- a therapeutic radiopharmaceutical agent described herein comprises a compound and a radionuclide, where the compound is or a pharmaceutically acceptable salt and/or solvate thereof.
- a compound of Formula (II-D1), (II-D2), or (II-D3) is or a pharmaceutically acceptable salt and/or solvate thereof, wherein M 1 is a radionuclide.
- modified antibody, modified antibody fragment, or modified binding peptide of the present technology it may be that the modified antibody, modified antibody fragment, or modified binding peptide comprises a moiety having the following structure wherein one of the hydrogens is being substituted by a linkage or a pharmaceutically acceptable salt and/or solvate thereof.
- modified antibody, modified antibody fragment, or modified binding peptide comprises a moiety having the following structure wherein one of the hydrogens is being substituted by a linkage or a pharmaceutically acceptable salt and/or solvate thereof.
- Table B Exemplary Preparation for Targeting Compounds of Formula (III-A), Formula (III-B1), Formula (IP-B2), Formula (III-C1), Formula (III- Dl), and Formula (III-D2).
- Amide coupling is typically mediated by any of several coupling reagents (e.g., HATU, EDC, DCC, HOBT, PyBOP, etc.), which are detailed elsewhere. (See generally Eric Valeur & Mark Bradley, Amide Bond Formation: Beyond the Myth of Coupling Reagents, 38 CHEM. SOC. REV.606 (2009).) These and other amide coupling strategies are described in a recent review by Tsuchikama. (Kyoji Tsuchikama & Zhiqiang An, Antibody-Drug Conjugates: Recent Advances in Conjugation and Linker Chemistries, 9 PROTEIN CELL 33, 36 (2018); see also, e.g., A.C.
- cysteine coupling reactions may be employed to conjugate prosthetic molecules with thiol-reactive termini to protein surfaces through exposed thiol side chains on cysteine residues on the protein (e.g., antibody) surface.
- cysteine residues readily form disulfide linkages with nearby cysteine residues under physiological conditions, rather than existing as free thiols, some cysteine coupling strategies may rely upon selective reduction of disulfides to generate a higher number of reactive free thiols.
- Cysteine coupling techniques known in the art include, but are not limited to, cys alkylation reactions, cysteine rebridging reactions, and cys-aryl coupling using organometallic palladium reagents.
- ADCs Antibody-Drug Conjugates
- CuAAC copper(I)-catalyzed azide-alkyne 1,3-dipolar cycloaddition reaction
- the CuAAC click reaction may be carried out in the presence of ligands to enhance reaction rates.
- ligands may include, for example, polydentate nitrogen donors, including amines (e.g., tris(triazolyl)methyl amines) and pyridines. (See Liang & Astruc, supra, at 2934 (collecting examples); P.L.
- Cu-free click methods are also known in the art for delivery of therapeutic and/or diagnostic agents, such as radionuclides (e.g., 18 F), chemotherapeutic agents, dyes, contrast agents, fluorescent labels, chemiluminescent labels, or other labels, to protein surfaces. Cu-free click methods may permit stable covalent linkage between target molecules and prosthetic groups.
- Cu-free click chemistry may include reacting an antibody or antigen- binding fragment, which has been modified with a non-natural amino acid side chain that includes an activating moiety such as a cyclooctyne (e.g., dibenzocyclooctyne (DBCO)), a nitrone or an azide group, with a prosthetic group that presents a corresponding or complementary reactive moiety, such as an azide, nitrone or cyclooctyne (e.g., DBCO).
- an activating moiety such as a cyclooctyne (e.g., dibenzocyclooctyne (DBCO)
- DBCO dibenzocyclooctyne
- a prosthetic group that presents a corresponding or complementary reactive moiety, such as an azide, nitrone or cyclooctyne (e.g., DBCO).
- the prosthetic group may include an azide, nitrone, or similar reactive moiety.
- the prosthetic group may present a complementary cyclooctyne, alkyne, or similar reactive moiety.
- Cu-free click reactions may be carried out at room temperature, in aqueous solution, in the presence of phosphate-buffered saline (PBS).
- the prosthetic group may be radiolabeled (e.g., with 18 F) or may be conjugated to any alternative diagnostic and/or therapeutic agent (e.g., a chelating agent). (See id. at 531.)
- Tripartite Compounds [0140] The compounds of any embodiment and aspect herein of the present technology may be a tripartite compound. However, such tripartite compounds are not restricted to compositions including Formulas (I), (II), or (III).
- a tripartite compound that includes a first domain that has relatively low but still specific affinity for serum albumin (e.g., 0.5 to 50 x 10 -6 M), a second domain including a chelating moiety such as but not limited to those described herein (e.g., a chelating moiety comprising or arising from a compound of Formula (I) or Formula (II)), and a third domain that includes tumor targeting moiety (TTT) having relatively high affinity for a tumor antigen (e.g., 0.5 to 50 x 10 -9 M).
- TTT tumor targeting moiety
- the following exemplary peptide receptors, enzymes, cell adhesion molecules, tumor associated antigens, growth factor receptors and cluster of differentiation antigens are useful targets for constructing the TTT domain: glypican-3 (GPC3) receptor, somatostatin peptide receptor-2 (SSTR2), gastrin- releasing peptide receptor, seprase (FAP-alpha), incretin receptors, glucose-dependent insulinotropic polypeptide receptors , VIP-1, NPY, folate receptor, LHRH, and ⁇ v ⁇ 3, an overexpressed peptide receptor, a neuronal transporter (e.g., noradrenaline transporter (NET)), or other tumor associated proteins such as EGFR, HER-2, VGFR, MUC-1, CEA, MUC-4, ED2,TF-antigen, endothelial specific markers, neuropeptide Y, uPAR, TAG-72, CCK analogs, VIP, bombesin, VEGFR, tumor-specific cell surface proteins, G
- TTT is independently at each occurrence a binding domain for a glypican-3 (GPC3) receptor, a somatostatin peptide receptor-2 (SSTR2), a gastrin-releasing peptide receptor, a seprase (FAP-alpha), an incretin receptor, a glucose-dependent insulinotropic polypeptide receptor, VIP-1, NPY, a folate receptor, LHRH, ⁇ v ⁇ 3, an overexpressed peptide receptor, a neuronal transporter (e.g., noradrenaline transporter (NET)), a receptor for a tumor associated protein (such as EGFR, HER-2, VGFR, MUC-1, CEA, MUC-4, ED2,TF-antigen, endothelial specific markers, neuropeptide Y, uPAR, TAG-72, CCK analogs, VIP, bombesin, VEGFR, tumor-specific cell surface proteins, GLP-1, CXCR4, Hepsin, TMPRSS2, caspaces,
- L 501 is independently at each occurrence absent, -C(O)-, -C(O)-NR 4 -, -C(O)-NR 5 -C 1 -C 12 alkylene-,-C 1 -C 12 alkylene-C(O)-, -C(O)-NR 6 -C 1 -C 12 alkylene-C(O)-, -arylene-, – O(CH 2 CH 2 O)r–CH 2 CH 2 C(O)–, –O(CH 2 CH 2 O) rr –CH 2 CH 2 C(O)–NH—, – O(CH 2 CH 2 O) rrr –CH 2 CH 2 —, an amino acid, a peptide of 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids, or a combination of any two or more thereof, where r is 0, 1, 2, 3, 4, 5, 6, 7, 8, or 9, rr is 0, 1, 2, 3, 4, 5, 6, 7, 8, or 9, rrr is 0, 1, 2, 3, 4, 5, 6, 7, 8, or
- the radionuclide may be 230 UO 2 2+ , 230 U 6+ , 67 Ga 3+ , 68 Ga 3+ , 64 Cu 2+ , or 111 In 3+ .
- it may be the tripartite compounds of Formulas (L)-(LIV) are of Formulas (LV)-(LIX) where L 503 is independently at each occurrence absent, -C(O)-, -C 1 -C 12 alkylene-,-C 1 -C 12 alkylene-C(O)-, -C 1 -C 12 alkylene-NR 10 -, -arylene-, –(CH 2 CH 2 O) z –CH 2 CH 2 C(O)–, – (CH 2 CH 2 O) zz –CH 2 CH 2 C(O)–NH–, –(CH 2 CH 2 O) zzz –CH 2 CH 2 –, an amino acid, —CH
- the albumin-binding moiety plays a role in modulating the rate of blood plasma clearance of the compounds in a subject, thereby increasing circulation time and compartmentalizing the cytotoxic action of cytotoxin-containing domain and/or imaging capability of the imaging agent-containing domain in the plasma space instead of normal organs and tissues that may express antigen.
- this component of the structure is believed to interact reversibly with serum proteins, such as albumin and/or cellular elements.
- the affinity of this albumin-binding moiety for plasma or cellular components of the blood may be configured to affect the residence time of the compounds in the blood pool of a subject.
- the albumin binding-moiety may be configured so that it binds reversibly or non-reversibly with albumin when in blood plasma. In any embodiment herein, the albumin binding-moiety may be selected such that the binding affinity of the compound with human serum albumin is about 5 ⁇ M to about 15 ⁇ M.
- the albumin-binding moiety of any embodiment herein may include a short- chain fatty acid, medium-chain chain fatty acid, a long-chain fatty acid, myristic acid, a substituted or unsubstituted indole-2-carboxylic acid, a substituted or unsubstituted 4- oxo-4-(5,6,7,8-tetrahydronaphthalen-2-yl)butanoic acid, a substituted or unsubstituted naphthalene acylsulfonamide, a substituted or unsubstituted diphenylcyclohexanol phosphate ester, a substituted or unsubstituted 2-(4-iodophenyl)acetic acid, a substituted or unsubstituted 3- (4-iodophenyl)propionic acid, or a substituted or unsubstituted 4-(4-iodophenyl)but
- the tripartite compounds may include an albumin-binding moiety that is where Y 501 502 , Y , Y 503 , Y 504 , and Y 505 are independently H, halo, or alkyl, X 503 , X 504 , X 505 , and X 506 are each independently O or S, aa is independently at each occurrence 0, 1, or 2, bb is independently at each occurrence 0 or 1, cc is independently at each occurrence 0 or 1, and dd is independently at each occurrence 0, 1, 2, 3, or 4. In any embodiment herein, it may be that bb and cc cannot be the same value.
- Y 503 is I and each of Y 501 , Y 502 , Y 503 , Y 504 , and Y 505 are each independently H.
- Representative chelators useful in any embodiment of the present technology include, but are not limited to, a covalently conjugated substituted or unsubstituted chelator of the following group: 6,6'-((ethane-1,2-diylbis(azanediyl))bis(methylene))dipicolinic acid (H 2 dedpa), 6,6'-((((1S,2S)-cyclohexane-1,2-diyl)bis(azanediyl))bis(methylene))dipicolinic acid (H 2 CHXdedpa), 2,2'-((ethane-1,2-diylbis(azanediyl))bis(methylene))bis(quinolin-8-ol) (H 2 ho
- a “covalently conjugated” chelator means a chelator (such as those listed above) wherein one or more bonds to a hydrogen atom contained therein are replaced by a bond to an atom of the remainder of the Rad and/or CHEL moiety, to L 501 , and/or to L 502 , or a pi bond between two atoms is replaced by a bond from one of the two atoms to an atom of the remainder of the Rad and/or CHEL moiety, to L 501 , and/or to L 502 , and the other of the two atoms includes a new bond, e.g. to a hydrogen.
- the CHEL of the tripartite compounds is a chelator as provided in the compounds of Formula (I), (II), or (III).
- tripartite compound may be a targeting compound of Formula (III) where R 21 , R 25 , R 26 , R 27 , and R 28 are each independently
- TTT may be an antibody.
- TTT may be codrituzumab (GC33), or a binding fragment thereof.
- TTT may be a targeting moiety that targets the glypican-3 (GPC3) receptor.
- TTT comprises a targeting moiety that targets the glypican-3 (GPC3) receptor.
- TTT may be any embodiment
- W 501 is –C(O)–, –(CH 2 ) ww –, or –(CH 2 ) oo –NH 2 -C(O)–; mm is 0 or 1; ww is 1 or 2; oo is 1 or 2;and P 501 , P 502 , and P 503 are each independently H, methyl, benzyl, 4-methoxybenzyl, or tert- butyl. [0152] In any embodiment herein, it may be that each of P 501 , P 502 , and P 503 are H.
- the tripartite compounds e.g., the tumor targeting domain
- the tripartite compounds comprise a moiety with one of the following structures, which may, e.g., target seprase (Fibroblast Activation Protein/FAP):
- target seprase Fibroblast Activation Protein/FAP
- the tripartite compounds of the present technology can include variations on any of the three domains: e.g., the domain including the chelator, the domain including the albumin-binding group, or the domain including the tumor targeting moiety.
- compositions e.g., pharmaceutical compositions
- medicaments comprising any of one of the embodiments of the compounds of Formulas (I), (II), (III); any one of therapeutic radiopharmaceutical agents comprising a chelator (e.g., compounds of Formulas (I)) and a radionuclide (e.g., 230 U); any one of the modified antibodies, modified antibody fragments, or modified binding peptides of the present technology disclosed herein; or any one of the embodiments of the tripartite compounds disclosed herein, and a pharmaceutically acceptable carrier or one or more excipients or fillers (collectively referred to as “pharmaceutically acceptable carrier” unless otherwise specified).
- a pharmaceutically acceptable carrier or one or more excipients or fillers
- compositions may be used in the methods and treatments described herein.
- the pharmaceutical composition may include an effective amount of any embodiment of the compounds of the present technology for treating the cancer and/or mammalian tissue overexpressing e.g., an antigen or a receptor; or an effective amount of any embodiment of the modified antibody, modified antibody fragment, or modified binding peptide of the present technology for treating the cancer and/or mammalian tissue overexpressing e.g., an antigen or a receptor; or an effective amount of any embodiment of the tripartite compound of the present technology for treating the cancer and/or mammalian tissue overexpressing e.g., an antigen or a receptor.
- a method of treating a subject includes administering a targeting compound of the present technology to the subject or administering a modified antibody, modified antibody fragment, or modified binding peptide of the present technology to the subject.
- a targeting compound of the present technology to the subject or administering a modified antibody, modified antibody fragment, or modified binding peptide of the present technology to the subject.
- the administering includes administering an effective amount of any embodiment of the compounds of the present technology for treating the cancer and/or mammalian tissue overexpressing, e.g., an antigen or a receptor of the compound or an effective amount of any embodiment of the modified antibody, modified antibody fragment, or modified binding peptide of the present technology for treating the cancer and/or mammalian tissue overexpressing, e.g., an antigen or a receptor or an effective amount of any embodiment of the tripartite compound of the present technology for treating the cancer and/or mammalian tissue overexpressing e.g., an antigen or a receptor.
- the subject may suffer from a mammalian tissue expressing glypican-3 (GPC3) receptor, a somatostatin receptor, a bombesin receptor, seprase, or a combination of any two or more thereof and/or mammalian tissue overexpressing PSMA.
- the mammalian tissue of any embodiment disclosed herein may include one or more of a growth hormone producing tumor, a neuroendocrine tumor, a pituitary tumor, a vasoactive intestinal peptide-secreting tumor, a small cell carcinoma of the lung, gastric cancer tissue, pancreatic cancer tissue, a neuroblastoma, and a metastatic cancer.
- the subject may suffer from one or more of a liver cancer, a glioma, a breast cancer, an adrenal cortical cancer, a cervical carcinoma, a vulvar carcinoma, an endometrial carcinoma, a primary ovarian carcinoma, a metastatic ovarian carcinoma, a non-small cell lung cancer, a small cell lung cancer, a bladder cancer, a colon cancer, a primary gastric adenocarcinoma, a primary colorectal adenocarcinoma, a renal cell carcinoma, and a prostate cancer.
- the composition e.g., pharmaceutical composition
- medicament may be formulated for parenteral administration.
- the composition e.g., pharmaceutical composition
- the administering step of the method may include parenteral administration.
- the administering step of the method may include intraveneous administration.
- the effective amount may be determined in relation to a subject. “Effective amount” refers to the amount of a compound or composition required to produce a desired effect.
- an effective amount includes amounts or dosages that yield acceptable toxicity and bioavailability levels for therapeutic (pharmaceutical) use including, but not limited to, the treatment of e.g., one or more of a glioma, a liver cancer, a breast cancer, an adrenal cortical cancer, a cervical carcinoma, a vulvar carcinoma, an endometrial carcinoma, a primary ovarian carcinoma, a metastatic ovarian carcinoma, a non- small cell lung cancer, a small cell lung cancer, a bladder cancer, a colon cancer, a primary gastric adenocarcinoma, a primary colorectal adenocarcinoma, a renal cell carcinoma, and a prostate cancer.
- an effective amount includes amounts or dosages that are capable of reducing symptoms associated with e.g., one or more of a glioma, a liver cancer, a breast cancer, an adrenal cortical cancer, a cervical carcinoma, a vulvar carcinoma, an endometrial carcinoma, a primary ovarian carcinoma, a metastatic ovarian carcinoma, a non- small cell lung cancer, a small cell lung cancer, a bladder cancer, a colon cancer, a primary gastric adenocarcinoma, a primary colorectal adenocarcinoma, a renal cell carcinoma, and a prostate cancer, such as, for example, reduction in proliferation and/or metastasis of liver cancer, prostate cancer, breast cancer, or bladder cancer.
- a glioma a liver cancer, a breast cancer, an adrenal cortical cancer, a cervical carcinoma, a vulvar carcinoma, an endometrial carcinoma, a primary ovarian carcinoma, a metastatic ovarian carcinoma, a non- small cell
- the effective amount may be from about 0.01 ⁇ g to about 1 mg of the compound per gram of the composition, and preferably from about 0.1 ⁇ g to about 500 ⁇ g of the compound per gram of the composition.
- a “subject” or “patient” is a mammal, such as a cat, dog, rodent or primate.
- the subject is a human, and, preferably, a human suffering from or suspected of suffering from one or more of a glioma, a liver cancer, a breast cancer, an adrenal cortical cancer, a cervical carcinoma, a vulvar carcinoma, an endometrial carcinoma, a primary ovarian carcinoma, a metastatic ovarian carcinoma, a non-small cell lung cancer, a small cell lung cancer, a bladder cancer, a colon cancer (such as colon adenocarcinoma), a primary gastric adenocarcinoma, a primary colorectal adenocarcinoma, a renal cell carcinoma, and a prostate cancer.
- the term “subject” and “patient” can be used interchangeably.
- the pharmaceutical composition may be packaged in unit dosage form.
- the unit dosage form is effective in treating one or more of a cancer, a liver cancer, a glioma, a breast cancer, an adrenal cortical cancer, a cervical carcinoma, a vulvar carcinoma, an endometrial carcinoma, a primary ovarian carcinoma, a metastatic ovarian carcinoma, a non-small cell lung cancer, a small cell lung cancer, a bladder cancer, a colon cancer (such as colon adenocarcinoma), a primary gastric adenocarcinoma, a primary colorectal adenocarcinoma, a renal cell carcinoma, and a prostate cancer.
- a unit dosage including a compound of the present technology will vary depending on patient considerations. Such considerations include, for example, age, protocol, condition, sex, extent of disease, contraindications, concomitant therapies and the like. An exemplary unit dosage based on these considerations may also be adjusted or modified by a physician skilled in the art.
- a unit dosage for a patient comprising a compound of the present technology may vary from 1 ⁇ 10 –4 g/kg to 1 g/kg, preferably, 1 ⁇ 10 –3 g/kg to 1.0 g/kg. Dosage of a compound of the present technology may also vary from 0.01 mg/kg to 100 mg/kg or, preferably, from 0.1 mg/kg to 10 mg/kg.
- Suitable unit dosage forms include, but are not limited to powders, tablets, pills, capsules, lozenges. suppositories. patches. nasal sprays, injectibles, implantable sustained-release formulations, rnucoadherent films, topical varnishes, lipid complexes, etc.
- the pharmaceutical compositions may be prepared by mixing one or more of the compounds of Formulas (I), (II), (III); or a therapeutic radiopharmaceutical agent comprising a chelator (e.g., compounds of Formulas (I)) and a radionuclide (e.g., 230 U); or any one of the modified antibodies, modified antibody fragments, or modified binding peptides of the present technology, or any embodiment of the tripartite compound of the present technology, pharmaceutically acceptable salts thereof, stereoisomers thereof, tautomers thereof, or solvates thereof, with pharmaceutically acceptable carriers, excipients, binders, diluents or the like to prevent and treat disorders associated with cancer (e.g., liver cancer) and/or a mammalian tissue overexpressing glypican-3 (GPC3) receptor.
- a therapeutic radiopharmaceutical agent comprising a chelator (e.g., compounds of Formulas (I)) and a radionuclide (e.g.,
- compositions described herein may be used to prepare formulations and medicaments that treat e.g., liver cancer, prostate cancer, breast cancer, or bladder cancer.
- Such compositions may be in the form of, for example, granules, powders, tablets, capsules, syrup, suppositories, injections, emulsions, elixirs, suspensions or solutions.
- the instant compositions may be formulated for various routes of administration, for example, by oral, parenteral, topical, rectal, nasal, vaginal administration, or via implanted reservoir.
- Parenteral or systemic administration includes, but is not limited to, subcutaneous, intravenous, intraperitoneal, and intramuscular, injections.
- the following dosage forms are given by way of example and should not be construed as limiting the instant present technology.
- powders, suspensions, granules, tablets, pills, capsules, gelcaps, and caplets are acceptable as solid dosage forms. These can be prepared, for example, by mixing one or more compounds of the instant present technology, or pharmaceutically acceptable salts or tautomers thereof, with at least one additive such as a starch or other additive.
- Suitable additives are sucrose, lactose, cellulose sugar, mannitol, maltitol, dextran, starch, agar, alginates, chitins, chitosans, pectins, tragacanth gum, gum arabic, gelatins, collagens, casein, albumin, synthetic or semi-synthetic polymers or glycerides.
- oral dosage forms can contain other ingredients to aid in administration, such as an inactive diluent, or lubricants such as magnesium stearate, or preservatives such as paraben or sorbic acid, or anti-oxidants such as ascorbic acid, tocopherol or cysteine, a disintegrating agent, binders, thickeners, buffers, sweeteners, flavoring agents or perfuming agents. Tablets and pills may be further treated with suitable coating materials known in the art.
- suitable coating materials known in the art.
- Liquid dosage forms for oral administration may be in the form of pharmaceutically acceptable emulsions, syrups, elixirs, suspensions, and solutions, which may contain an inactive diluent, such as water.
- Pharmaceutical formulations and medicaments may be prepared as liquid suspensions or solutions using a sterile liquid, such as, but not limited to, an oil, water, an alcohol, and combinations of these.
- Pharmaceutically suitable surfactants, suspending agents, emulsifying agents may be added for oral or parenteral administration.
- suspensions may include oils.
- oils include, but are not limited to, peanut oil, sesame oil, cottonseed oil, com oil and olive oil.
- Suspension preparation may also contain esters of fatty acids such as ethyl oleate, isopropyl myristate, fatty acid glycerides and acetylated fatty acid glycerides.
- Suspension formulations may include alcohols, such as, but not limited to, ethanol, isopropyl alcohol, hexadecyl alcohol, glycerol and propylene glycol.
- Injectable dosage forms generally include aqueous suspensions or oil suspensions which may be prepared using a suitable dispersant or wetting agent and a suspending agent. Injectable forms may be in solution phase or in the form of a suspension, which is prepared with a solvent or diluent. Acceptable solvents or vehicles include sterilized water, Ringer's solution, or an isotonic aqueous saline solution. Alternatively, sterile oils may be employed as solvents or suspending agents.
- the oil or fatty acid is non-volatile, including natural or synthetic oils, fatty acids, mono-, di- or tri-glycerides.
- the pharmaceutical formulation and/or medicament may be a powder suitable for reconstitution with an appropriate solution as described above. Examples of these include, but are not limited to, freeze dried, rotary dried or spray dried powders, amorphous powders, granules, precipitates, or particulates.
- the formulations may optionally contain stabilizers, pH modifiers, surfactants, bioavailability modifiers and combinations of these.
- Compounds of the present technology may be administered to the lungs by inhalation through the nose or mouth.
- Suitable pharmaceutical formulations for inhalation include solutions, sprays, dry powders, or aerosols containing any appropriate solvents and optionally other compounds such as, but not limited to, stabilizers, antimicrobial agents, antioxidants, pH modifiers, surfactants, bioavailability modifiers and combinations of these.
- the carriers and stabilizers vary with the requirements of the particular compound, but typically include nonionic surfactants (Tweens, Pluronics, or polyethylene glycol), innocuous proteins like serum albumin, sorbitan esters, oleic acid, lecithin, amino acids such as glycine, buffers, salts, sugars or sugar alcohols.
- Aqueous and nonaqueous aerosols are typically used for delivery of compounds of the present technology by inhalation.
- pharmaceutically acceptable excipients and carriers are generally known to those skilled in the art and are thus included in the instant present technology. Such excipients and carriers are described, for example, in “Remingtons Pharmaceutical Sciences” Mack Pub. Co., New Jersey (1991), which is incorporated herein by reference.
- the instant compositions may also include, for example, micelles or liposomes, or some other encapsulated form.
- Specific dosages may be adjusted depending on conditions of disease, the age, body weight, general health conditions, sex, and diet of the subject, dose intervals, administration routes, excretion rate, and combinations of drugs. Any of the above dosage forms containing effective amounts are well within the bounds of routine experimentation and therefore, well within the scope of the instant present technology. [0167] Various assays and model systems can be readily employed to determine the therapeutic effectiveness of the treatment according to the present technology.
- test subjects will exhibit a 10%, 20%, 30%, 50% or greater reduction, up to a 75–90%, or 95% or greater, reduction, in one or more symptom(s) caused by, or associated with, the disorder in the subject, compared to placebo–treated or other suitable control subjects.
- the present technology provides a method of treating cancer by administering an effective amount of the targeting composition according to Formula (III) to a subject having cancer. Since a cancer cell targeting agent can be selected to target any of a wide variety of cancers, the cancer considered herein for treatment is not limited.
- the cancer can be essentially any type of cancer.
- antibodies or peptide vectors can be produced to target any of a wide variety of cancers.
- the targeting compositions described herein are typically administered by injection into the bloodstream, but other modes of administration, such as oral or topical administration, are also considered.
- the targeting composition may be administered locally, at the site where the target cells are present, i.e., in a specific tissue, organ, or fluid (e.g., blood, cerebrospinal fluid, etc.). Any cancer that can be targeted through the bloodstream is of particular consideration herein.
- a specific tissue, organ, or fluid e.g., blood, cerebrospinal fluid, etc.
- Any cancer that can be targeted through the bloodstream is of particular consideration herein.
- Some examples of applicable body parts containing cancer cells include the breasts, lungs, stomach, intestines, prostate, ovaries, cervix, pancreas, kidney, liver, skin, lymphs, bones, bladder, uterus, colon, rectum, and brain.
- the cancer can also include the presence of one or more carcinomas, sarcomas, lymphomas, blastomas, or teratomas (germ cell tumors).
- the cancer may also be a form of leukemia.
- the cancer is a triple negative breast cancer.
- the cancer is a liver cancer.
- a suitable dosage of the targeting composition may be precisely, at least, above, up to, or less than, for example, 1 mg, 10 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 700 mg, 800 mg, 900 mg, 1000 mg, 1200 mg, or 1500 mg, or a dosage within a range bounded by any of the foregoing exemplary dosages.
- compositions can be administered in the indicated amount by any suitable schedule, e.g., once, twice, or three times a day or on alternate days for a total treatment time of one, two, three, four, or five days, or one, two, three, or four weeks, or one, two, three, four, five, or six months, or within a time frame therebetween.
- schedule e.g., once, twice, or three times a day or on alternate days for a total treatment time of one, two, three, four, or five days, or one, two, three, or four weeks, or one, two, three, four, five, or six months, or within a time frame therebetween.
- the composition can be administered until a desired change in the disorder or condition is realized, or when a preventative effect is believed to be provided.
- the examples herein are provided to illustrate advantages of the present technology and to further assist a person of ordinary skill in the art with preparing or using the compounds of the present technology or salts, pharmaceutical compositions, derivatives, prodrugs, or
- Deionized water ( ⁇ 18 M ⁇ ) was obtained from an Elga Purelab Flex 2 water purification system.
- Analytical high performance liquid chromatography HPLC was performed using a LC- 20AT pump with an SPD-20AV UV-vis detector monitored at 270 and 220 nm (Shimadzu, Japan) and an Ultra Aqueous C18 column (100 ⁇ , 5 ⁇ m, 250 mm ⁇ 4.6 mm; Restek, Bellefonte, PA) at a flow rate of 1 mL/min. All methods employed a binary mobile phase.
- Method A1 (A) H 2 O + 0.1% TFA; (B) MeOH + 0.1% TFA; 0-5 min 10% B, 5-25 min linear gradient to 100% B, 25-30 min 100% B, 30-35 min linear gradient to 10% B.
- Method A2 (A) H 2 O + 50 mM NH 4 OAc; (B) MeOH + 50 mM NH 4 OAc, 0-5 min 10% B, 5-25 min linear gradient to 100% B, 25-30 min 100% B, 30-35 min linear gradient to 10% B.
- Method A3 (A) H 2 O + 50 mM NH 4 OAc; (B) MeOH + 50 mM NH 4 OAc, 0-5 min 10% B, 5-15 min linear gradient to 100% B, 15-20 min 100% B, 20- 25 min linear gradient to 10% B.
- Method A4 (A) H 2 O + 10 mM NH 4 HCO 3 ; (B) 90% MeOH + 10% H 2 O + 10 mM NH 4 HCO 3 , 0-5 min 10% B, 5-15 min linear gradient to 100% B, 15-20 min 100% B, 20-25 min linear gradient to 10% B.
- Method P1 (A) H 2 O + 0.1% TFA; (B) MeOH + 0.1% TFA; 0-5 min 10% B, 5-25 min linear gradient to 100% B, 25-30 min 100% B, 30-35 min linear gradient to 10% B.
- NMR spectra were obtained at 25 °C using a Varian Inova 600 MHz spectrometer equipped with a H ⁇ C/N ⁇ probe with XYZ-PFG, a Bruker AV III HD 400 MHz spectrometer equipped with a broadband BBFO probe, or a Bruker AV III HD 500 MHz spectrometer equipped with a broadband Prodigy cryoprobe.
- Samples containing 238 U were obtained using a Varian Inova 500 MHz spectrometer equipped with a 1 H/BB nanoprobe with Z-PFG. Chemical shifts are reported in ppm and were referenced to the residual solvent signal.
- Spectra acquired in D 2 O were spiked with 0.1% dioxane, 0.1% acetone, or 0.1% DMSO-d 6 as an internal reference.
- Spectra of samples containing 238 U were collected in an NMR tube fitted with a PTFE liner (C-TL-5-7; Chemglass Life Sciences, Vineland, NJ) to prevent release of 238 U in the case of a tube break.
- MS High resolution mass spectra
- MS were recorded on an Exactive Orbitrap mass spectrometer (ThermoFisher) in positive ion electrospray ionization (ESI) mode with samples injected as acetonitrile/water solutions with 1% formic acid or direct analysis in real time (DART) mode with samples dissolved in chloroform.
- UV-vis spectra were recorded using 1 cm quartz cuvettes and a Shimadzu UV-1900 spectrometer (Shimadzu, Kyoto, Japan) fitted with a temperature-controlled circulating water bath. Infrared spectra were recorded in KBr pellets using a Nicolet Avatar 370 DTGS (ThermoFisher Scientific, Waltham, MA).
- Elemental analyses were carried out by Atlantic Microlab Inc. (Norcross, GA).
- Uranium stock solutions were prepared either by dissolving a weighed amount of UO 2 (NO 3 ) 2 ⁇ 6H 2 O in 0.1M HCl for the complexation kinetics studies or from an inductively coupled plasma standardized solution (9992 ⁇ 44 ⁇ g/mL, 2 % v/v HNO 3 ; BDH Chemicals) for all other studies and the exact concentration was determined using arsenazo III with a calibration curve prepared using a series of UO 2 (NO 3 ) 2 solutions with known concentration.
- Synthesis and Characterization of H 2 dedpa H 2 dedpa was prepared according to below procedure.
- Ethylene diamine (380 ⁇ L, 5.7 mmol) was dissolved in MeOH (38 mL) and added dropwise to a solution of S2 (1.9 g, 11.5 mmol) in boiling MeOH (115 mL) with rapid stirring. The resulting solution was heated at reflux for 30 min and allowed to cool to RT. The yellow solution was filtered, and the solvent was removed by rotary evaporation to give a yellow residue, which was suspended in Et 2 O (40 mL) and filtered to furnish a white powder. Yield: 1.44 g, 4.06 mmol (71%).
- H 2 CHXdedpa H 2 CHXdedpa was prepared according to below procedure. [0190] ( ⁇ )- ⁇ [(6-(methoxycarbonyl)pyridin-2-yl)-methylene]amino ⁇ -cyclohexane (S5).
- H 2 hox was prepared according to below procedure.
- 2-formyl-8-hydroxyquinoline (S7) A mixture of dioxane (300 mL) and water (3 mL) was bubbled with Ar for 30 min and transferred via cannula to a flask containing 2-methyl-8-hyroxyquinoline (4.067 g, 25.5 mmol) and SeO 2 (3.55 g, 32.03 mmol) under an Ar atmosphere. The resulting suspension was heated at 80 °C for 24 h under an Ar atmosphere to yield an orange solution, which was cooled to RT and filtered to remove elemental Se.
- H 2 CHXhox was prepared according to below procedure.
- S9 2,2'-[( ⁇ )-1,2-cyclohexanediylbis(nitrliomethylidyne)]bis(8-quinolinol) (S9).
- S9 2,2'-[( ⁇ )-1,2-cyclohexanediylbis(nitrliomethylidyne)]bis(8-quinolinol) (S9).
- S7 1.017 g, 5.87 mmol
- Triethylamine (61 ⁇ L, 0.441 mmol) was added to a methanolic solution (6 mL) of H 2 CHXdedpa ⁇ 2HCl (0.0717 g, 0.152 mmol) and stirred at room temperature.
- a solution of UO 2 (NO 3 ) 2 ⁇ 6H 2 O (0.0482 g, 0.096 mmol) in MeOH (1 mL) was added dropwise to the reaction mixture to give a bright yellow solution with almost immediate formation of a pale yellow precipitate.
- the suspension was heated at reflux for 13 h, allowed to cool to RT, and added to an equal volume of Et 2 O to fully precipitate the product.
- Triethylamine (27 ⁇ L, 0.193 mmol) was added to a methanolic solution (3 mL) of H 2 hox ⁇ 2HCl (0.0294 g, 0.0657 mmol) and stirred at room temperature.
- a solution of UO 2 (NO 3 ) 2 ⁇ 6H 2 O (0.0212 g, 0.0421 mmol) in MeOH (0.5 mL) was added dropwise to the reaction mixture, which rapidly changed color from yellow to orange to brown with formation of a brown precipitate.
- the suspension was heated at reflux for 18 h and cooled to RT before an equal volume of Et 2 O was added to fully precipitate the product, which was collected by centrifugation.
- Triethylamine (56 ⁇ L, 0.4 mmol) was added to a methanolic solution (6 mL) of H 2 CHXhox ⁇ 2HCl (0.0502 g, 0.089 mmol) and stirred at room temperature.
- the suspension was heated at reflux for 16 h and cooled to RT before an equal volume of Et 2 O was added to fully precipitate the product, which was collected by centrifugation.
- the ligand protonation constants were measured by adding KOH to an aqueous solution ( ⁇ 20 mL) containing ligand ( ⁇ 1 mM) and HCl (5 mM). The ionic strength of the solution was maintained at 0.1 M using KCl.
- the titration method employed a 0.1 mV min -1 drift limit with a minimum and maximum wait time of 10 s and 200 s respectively between addition of aliquots of base.
- the titration data was analyzed using Hyperquad2013. Results are summarized in Table 1. [0217] In Situ Spectrophotometric Titration.
- Stock solutions of the ligands were prepared in pure water at a typical concentration of approximately 1.5 mM for H 2 hox or 10 mM for H 2 CHXhox, and the exact concentration was determined by quantitative NMR spectroscopy in triplicate.
- Titration solutions were prepared containing the ligand ( ⁇ 25 ⁇ M) and 500 ⁇ M (20 equiv.) each of MOPS, MES, and CHES to dampen the pH change upon addition of base.
- the ionic strength of each titration solution was maintained at 0.1 M using KCl. The solution was allowed to equilibrate with stirring for 15 min before addition of 0.01 – 1 mL aliquots of KOH.
- the pH of each sample was adjusted with standardized 1 M or 0.1 M HCl to span the range 0.7 ⁇ pH ⁇ 2.4 (H 2 dedpa and H 2 CHXdedpa) or 2.4 ⁇ pH ⁇ 7 (H 2 hox and H 2 CHXhox).
- pH ⁇ 1 the ionic strength was adjusted to 0.1 M with KCl.
- pH ⁇ 1 the ionic strength was dictated by the HCl concentration. All samples were allowed to equilibrate at 25 °C for at least 24 h. The pH-dependent spectroscopic data were analyzed using HypSpec 2014.
- a ⁇ is the final absorbance value
- At is the absorbance at time t.
- Absorbance was measured at 265 nm for H 2 dedpa, 268 nm for H 2 CHXdedpa, 260 nm for H 2 hox, and 260 nm for H 2 CHXhox.
- the second order rate constant k 2 (M -1 s -1 ) for the complexation reaction was then calculated as the linear slope of kobs vs. [H 2 L]. Results are summarized in Table 2. Table 2.
- Second-Order Rate Constants (k 2 , M –1 s –1 ) and Half-Lives (t 1/2 , s) for the Complexation of UO 2 2+ by the Ligands at 25 °C in Aqueous Solution.
- the second-order half-lives for the complexation reactions calculated using concentrations of 10 ⁇ M for both L and UO 2 2+ , are all under 4 min.
- the complexation kinetics for H 2 hox and H 2 CHXhox showed a marked dependence on pH with significantly smaller second-order rate constants obtained at pH 5 compared to pH 7.4, which may be a consequence of the fact that the ligands are fully protonated at lower pH.
- H 2 CHXdedpa the binding kinetics of the less basic H 2 dedpa and H 2 CHXdedpa ligands are relatively invariant to these two pH conditions.
- Comparison of the complexation kinetics of H 2 CHXdedpa and H 2 depda highlights the favorable effect of the preorganized CHX backbone towards metal chelation; H 2 CHXdedpa can sequester free uranium twice as fast as its en-based counterpart.
- the CHX group appears to have little influence on the complexation kinetics of H 2 hox and H 2 CHXhox.
- HAP hydroxyapatite
- caffeine 20 ⁇ M; H 2 CHXdedpa and H 2 CHXhox) or thiourea (1 mM; H 2 dedpa and H 2 hox) as an internal standard for HPLC analysis.
- the final complex concentration was 50 ⁇ M for UO 2 (dedpa) and UO 2 (CHXdedpa), 20 ⁇ M for H 2 hox, and 5 ⁇ M H 2 CHXhox.
- Uranyl nitrate in 1% nitric acid was purchased from International Bio- Analytical Industries (Boca Raton, FL) and used for complexation as described, and buffered to a final pH of 7 in sodium bicarbonate and Tris prior to injection.
- ligand evaluation groups a 1:0.7 ratio of ligand to metal was used.
- animals were sacrificed by CO 2 asphyxiation and organs of interest harvested.
- the organs were digested in ultra pure nitric acid (FisherSci) in trace metal-free vessels with a graded heating protocol from 65 ⁇ C by 10 ⁇ C for 15 min increments and then maintained at 95 ⁇ C for 1 h (DigiTUBE and DigiPREP Jr.; SCP Science, Montreal, Canada).
- the digested tissues were filtered through 0.45 ⁇ m polyethersulfone polymer membranes (Autofill; Foxx Life Science, Salem, NH) after dilution with deionized water to 14% nitric acid content, and then further diluted for analysis to 1-3%.
- a compound of Formula (I) or a pharmaceutically acceptable salt and/or solvate thereof wherein Z 1 is R 5 , and Z 2 is R 6 ; or Z 1 and Z 2 taken together are a C4 alkylene group optionally substituted by R 9 ; Z 3 is R 7 , and Z 4 is C(O); or Z 3 and Z 4 taken together with the carbon atoms to which they are bound are a 6-membered aryl ring optionally substituted by R 10 ; Z 5 is R 8 , and Z 6 is C(O); or Z 5 and Z 6 are taken together with the carbon atoms to which they are bound are a 6-membered aryl ring optionally substituted by R 11 ; R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 are each independently H, OH, NH 2 , SH, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl
- a therapeutic radiopharmaceutical agent comprising a chelator and a radionuclide; wherein the chelator is a compound of Formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, wherein Z 1 is R 5 , and Z 2 is R 6 ; or Z 1 and Z 2 taken together are a C 4 alkylene group optionally substituted by R 9 ; Z 3 is R 7 , and Z 4 is C(O); or Z 3 and Z 4 taken together with the carbon atoms to which they are bound are a 6-membered aryl ring optionally substituted by R 10 ; Z 5 is R 8 , and Z 6 is C(O); or Z 5 and Z 6 are taken together with the carbon atoms to which they are bound are a 6-membered aryl ring optionally substituted by R 11 ; R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 are each independently H, OH, NH 2 , SH,
- the therapeutic radiopharmaceutical agent of Paragraph J wherein Z 1 and Z 2 taken together are a C 4 alkylene group optionally substituted by R 9 .
- the therapeutic radiopharmaceutical agent of Paragraph J or K wherein the compound of Formula (I) is a compound of Formula (I-A) or a pharmaceutically acceptable salt and/or solvate thereof.
- N The therapeutic radiopharmaceutical agent of Paragraph M, wherein the compound of Formula (I-A) is a compound of Formula (I-A*) or Formula (I-A**) or a pharmaceutically acceptable salt and/or solvate thereof.
- O. The therapeutic radiopharmaceutical agent of any one of Paragraphs J, K, and M, wherein the chelator compound is , or a pharmaceutically acceptable salt and/or solvate thereof.
- the therapeutic radiopharmaceutical agent of Paragraph O wherein the chelator compound is , or a pharmaceutically acceptable salt and/or solvate thereof.
- Q The therapeutic radiopharmaceutical agent of any one of Paragraphs J-L, wherein the compound of Formula (I) is a compound of Formula (I-Bl) or Formula (I-B2), or a pharmaceutically acceptable salt and/or solvate thereof.
- R The therapeutic radiopharmaceutical agent of any one of Paragraphs J-L and Q, wherein the compound of Formula (I-Bl) or Formula (I-B2) is a compound of Formula (I-Bl*), Formula (I-Bl**), Formula (I-B2*), or Formula (I-B2**), or a pharmaceutically acceptable salt and/or solvate thereof.
- a compound of Formula (II) or a pharmaceutically acceptable salt and/or solvate thereof wherein M 1 is 230 U 67 Ga, 68 Ga, 64 Cu, or 111 In, optionally where M 1 is 230 UO 2 2+ , 230 U 6+ , 67 Ga 3+ , 6 8 Ga 3+ , 64 Cu 2+ , or 111 In 3+ ; Z 1 is R 5 , and Z 2 is R 6 ; or Z 1 and Z 2 taken together are a C 4 alkylene group optionally substituted by R 9 ; Z 3 is R 7 , and Z 4 is C(O); or Z 3 and Z 4 taken together with the carbon atoms to which they are bound are a 6-membered aryl ring optionally substituted by R 10 ; Z 5 is R 8 , and Z 6 is C(O); or Z 5 and Z 6 are taken together with the carbon atoms to which they are bound are a 6-membered aryl ring optionally substituted by R 11 ; R 1 , R 2
- R 21 , R 25 , R 26 , R 27 , and R 28 each independently comprises codrituzumab (GC33), belimumab, Mogamulizumab, Blinatumomab, Ibritumomab tiuxetan, Obinutuzumab, Ofatumumab, Rituximab, Inotuzumab ozogamicin, Moxetumomab pasudotox, Brentuximab vedotin, Daratumumab, Ipilimumab, Cetuximab, Necitumumab, Panitumumab, Dinutuximab, Pertuzumab, Trastuzumab, Trastuzumab emtansine, Siltuximab, Cemiplimab, Nivolumab, Pembrolizumab, Olaratumab, At
- the targeting compound of Paragraph NN or OO wherein the compound is a compound of Formula (III-A) or a pharmaceutically acceptable salt and/or solvate thereof.
- QQ The targeting compound of Paragraph PP, wherein the compound is a compound of
- the targeting compound of Paragraph NN or OO wherein the compound is a compound of Formula (III-B1) or Formula (III-B2) pharmaceutically acceptable salt and/or solvate thereof.
- the targeting compound of Paragraph RR wherein the compound is a compound of Formula (III-B1*), Formula (III-B1**), or Formula (III-B2*), or Formula (III-B2**)
- the targeting compound of Paragraph NN or OO wherein the compound is a compound of Formula (III-C1) or Formula (III-C2) or a pharmaceutically acceptable salt and/or solvate thereof.
- VV The therapeutic radiopharmaceutical agent of any one of Paragraphs NN-UU, wherein M 1 is 230 UO 2 .
- WW A modified antibody, modified antibody fragment, or modified binding peptide comprising a linkage arising from conjugation of a compound of Formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, or a pharmaceutically acceptable salt and/or solvate thereof, with an antibody, antibody fragment, or binding peptide, wherein Z 1 is R 5 , and Z 2 is R 6 ; or Z 1 and Z 2 taken together are a C 4 alkylene group optionally substituted by R 9 ; Z 3 is R 7 , and Z 4 is C(O); or Z 3 and Z 4 taken together with the carbon atoms to which they are bound are a 6-membered aryl ring optionally substituted by R 10 ; Z 5 is R 8 , and Z 6 is C(O); or Z 5 and Z 6 are taken together with the carbon
- the modified antibody, modified antibody fragment, or modified binding peptide of Paragraph WW wherein the antibody comprises codrituzumab (GC33), belimumab, Mogamulizumab, Blinatumomab, Ibritumomab tiuxetan, Obinutuzumab, Ofatumumab, Rituximab, Inotuzumab ozogamicin, Moxetumomab pasudotox, Brentuximab vedotin, Daratumumab, Ipilimumab, Cetuximab, Necitumumab, Panitumumab, Dinutuximab, Pertuzumab, Trastuzumab, Trastuzumab emtansine, Siltuximab, Cemiplimab, Nivolumab, Pembrolizumab, Olaratumab, Atezolizumab, Avelum
- the modified antibody, modified antibody fragment, or modified binding peptide of Paragraph WW wherein the antibody fragment comprises an antigen-binding fragment of codrituzumab (GC33), belimumab, Mogamulizumab, Blinatumomab, Ibritumomab tiuxetan, Obinutuzumab, Ofatumumab, Rituximab, Inotuzumab ozogamicin, Moxetumomab pasudotox, Brentuximab vedotin, Daratumumab, Ipilimumab, Cetuximab, Necitumumab, Panitumumab, Dinutuximab, Pertuzumab, Trastuzumab, Trastuzumab emtansine, Siltuximab, Cemiplimab, Nivolumab, Pembrolizumab, Olaratumab,
- CCC The modified antibody, modified antibody fragment, or modified binding peptide of Paragraph AAA, wherein the compound of Formula (I-B1) or Formula (I-B2) is a compound of Formula (I-B1*), Formula (I-B1**), Formula (I-B2*), or Formula (I- B2**), or a pharmaceutically acceptable salt and/or solvate thereof.
- DDD The modified antibody, modified antibody fragment, or modified binding peptide of any one of Paragraphs WW-YY, wherein the compound of Formula (I) is a compound of Formula (I-B1) or Formula (I-B2), or a pharmaceutically acceptable salt and/or solvate thereof.
- the modified antibody, modified antibody fragment, or modified binding peptide of any one of Paragraphs WW-YY wherein the compound of Formula (I) is a compound of Formula (I-C1) or Formula (I-C2), or a pharmaceutically acceptable salt and/or solvate thereof.
- EEE The modified antibody, modified antibody fragment, or modified binding peptide of any one of Paragraphs WW-YY, wherein the compound of Formula (I) is a compound of Formula (I-D1), Formula (I-D2), or Formula (I-D3) or a pharmaceutically acceptable salt and/or solvate thereof.
- FFF is a compound of Formula (I-D1), Formula (I-D2), or Formula (I-D3) or a pharmaceutically acceptable salt and/or solvate thereof.
- a modified antibody, modified antibody fragment, or modified binding peptide comprising a linkage arising from conjugation of a compound of Formula (II) or a pharmaceutically acceptable salt and/or solvate thereof, with an antibody, antibody fragment, or binding peptide, wherein M 1 is 230 U, 67 Ga, 68 Ga, 64 Cu, or 111 In, optionally where M 1 is 230 UO 2 2+ , 230 U 6+ , 67 Ga 3+ , 6 8 Ga 3+ , 64 Cu 2+ , or 111 In 3+ ; Z 1 is R 5 , and Z 2 is R 6 ; or Z 1 and Z 2 taken together are a C 4 alkylene group optionally substituted by R 9 ; Z 3 is R 7 , and Z 4 is C(O); or Z 3 and Z 4 taken together with the carbon atoms to which they are bound are a 6-membered aryl ring optionally substituted by R 10 ; Z 5 is R 8 , and Z 6 is C(O); or Z 5 and Z
- the modified antibody, modified antibody fragment, or modified binding peptide of Paragraph EEE wherein the antibody comprises codrituzumab (GC33), belimumab, Mogamulizumab, Blinatumomab, Ibritumomab tiuxetan, Obinutuzumab, Ofatumumab, Rituximab, Inotuzumab ozogamicin, Moxetumomab pasudotox, Brentuximab vedotin, Daratumumab, Ipilimumab, Cetuximab, Necitumumab, Panitumumab, Dinutuximab, Pertuzumab, Trastuzumab, Trastuzumab emtansine, Siltuximab, Cemiplimab, Nivolumab, Pembrolizumab, Olaratumab, Atezolizumab, Avelum
- Paragraph JJJ wherein the compound of Formula (II-B) is a compound of Formula (II- Bl*), Formula (II-Bl**), Formula (II-B2*), or Formula (II-B2**). or a pharmaceutically acceptable salt and/or solvate thereof.
- MMM The modified antibody, modified antibody fragment, or modified binding peptide of any one of Paragraphs EEE-HHH, wherein the compound of Formula (II) is a compound of Formula (II-C1) or Formula (II-C2), or a pharmaceutically acceptable salt and/or solvate thereof.
- NNN The modified antibody, modified antibody fragment, or modified binding peptide of any one of Paragraphs EEE-HHH, wherein the compound of Formula (II) is a compound of Formula (II-C1) or Formula (II-C2), or a pharmaceutically acceptable salt and/or solvate thereof.
- the modified antibody, modified antibody fragment, or modified binding peptide of any one of Paragraphs EEE-HHH wherein the compound of Formula (II) is a compound of Formula (II-D1), Formula (II-D2) or Formula (II-D3), or a pharmaceutically acceptable salt and/or solvate thereof.
- OOO The modified antibody, modified antibody fragment, or modified binding peptide of any one of Paragraphs EEE-NNN, wherein M 1 is 230 UO 2 .
- PPP A composition comprising a pharmaceutically acceptable carrier and a compound of any one of Paragraphs A-I and Z-MM, or a therapeutic radiopharmaceutical agent of any one of Paragraphs J-Y. QQQ.
- a composition comprising a pharmaceutically acceptable carrier and a targeting compound of any one of Paragraphs NN-VV or comprising a pharmaceutically acceptable carrier and a modified antibody, modified antibody fragment, or modified binding peptide of any one of Paragraphs WW-NNN.
- RRR A pharmaceutical composition useful in targeted radiotherapy of cancer and/or mammalian tissue in a subject, wherein the pharmaceutical composition comprises a pharmaceutically acceptable carrier and a compound of any one of Paragraphs NN-VV or a modified antibody, modified antibody fragment, or modified binding peptide of any one of Paragraphs WW-NNN.
- the pharmaceutical composition of Paragraph RRR wherein the pharmaceutical composition comprises an effective amount for treating the cancer and/or mammalian tissue of the compound, or an effective amount for treating the cancer and/or mammalian tissue of the modified antibody, modified antibody fragment, or modified binding peptide.
- TTT The pharmaceutical composition of any one of Paragraphs PPP-SSS, wherein the subject suffers from one or more of, a growth hormone producing tumor, a neuroendocrine tumor, a pituitary tumor, a vasoactive intestinal peptide-secreting tumor, a small cell carcinoma of the lung, gastric cancer tissue, pancreatic cancer tissue, and a neuroblastoma.
- any one of Paragraphs PPP-TTT wherein the subject suffers from one or more of a liver cancer, a glioma, a breast cancer, an adrenal cortical cancer, a cervical carcinoma, a vulvar carcinoma, an endometrial carcinoma, a primary ovarian carcinoma, a metastatic ovarian carcinoma, a non-small cell lung cancer, a small cell lung cancer, a bladder cancer, a colon cancer, a primary gastric adenocarcinoma, a primary colorectal adenocarcinoma, a renal cell carcinoma, and a prostate cancer.
- a liver cancer a glioma, a breast cancer, an adrenal cortical cancer, a cervical carcinoma, a vulvar carcinoma, an endometrial carcinoma, a primary ovarian carcinoma, a metastatic ovarian carcinoma, a non-small cell lung cancer, a small cell lung cancer, a bladder cancer, a colon cancer, a primary gastric adenocarcinoma,
- the pharmaceutical composition of any one of Paragraphs PPP-UUU wherein the pharmaceutical composition is formulated for intraveneous administration, optionally comprising sterilized water, Ringer's solution, or an isotonic aqueous saline solution.
- WWW The pharmaceutical composition of any one of PPP-VVV, wherein the effective amount of the compound is from about 0.01 ⁇ g to about 10 mg of the compound per gram of the pharmaceutical composition.
- XXX The pharmaceutical composition of any one of Paragraphs PPP-WWW, wherein the pharmaceutical composition is provided in an injectable dosage form.
- a method of treating a subject comprising administering a targeting compound of any one of Paragraphs NN-VV to the subject or administering a modified antibody, modified antibody fragment, or modified binding peptide of any one of Paragraphs WW-NNN.
- AAAA The method of Paragraph YYY or ZZZ, wherein the administering comprises parenteral administration.
- CCCC The method of any one of Paragraphs YYY-BBBB, wherein the effective amount is from about 0.1 ⁇ g to about 50 ⁇ g per kilogram of subject mass.
- a compound comprising a first domain having a blood-protein binding moiety with low specific affinity for the blood-protein, a second domain having a targeting antibody or a fragment thereof, and a third domain having a chelator.
- the compound of Paragraph DDDD wherein the blood protein binding moiety has specific affinity for albumin of about 0.5-50 x 10 -6 M, and the targeting antibody or a fragment thereof has specific affinity of about 0.5-50 x 10 -9 M.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La présente technologie concerne des composés, ainsi que des compositions comprenant de tels composés, utiles en radiothérapie ciblée (par exemple, une thérapie à l'uranium) de cancer et/ou de tissu de mammifère surexprimant, par exemple, un antigène ou un récepteur, les composés étant représentés par les formules suivantes ou par un de leurs sels et/ou solvates pharmaceutiquement acceptables, M1 étant indépendamment, à chaque occurrence, un radionucléide. L'invention divulgue également des équivalents de tels composés.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163193434P | 2021-05-26 | 2021-05-26 | |
US63/193,434 | 2021-05-26 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2022251516A2 true WO2022251516A2 (fr) | 2022-12-01 |
WO2022251516A3 WO2022251516A3 (fr) | 2023-01-26 |
Family
ID=84230354
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2022/031157 WO2022251516A2 (fr) | 2021-05-26 | 2022-05-26 | Complexes à chélateurs acycliques et leur utilisation en radiothérapie ciblée de cancer |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2022251516A2 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024155993A1 (fr) * | 2023-01-20 | 2024-07-25 | The Board Of Regents Of The University Of Texas System | Agents théranostiques ciblés pour l'imagerie et le traitement d'un cancer |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2783275A1 (fr) * | 2003-07-24 | 2005-02-03 | Bracco Imaging S.P.A. | Compositions radiopharmaceutiques stables et methodes pour leur preparation |
CN104780944B (zh) * | 2012-09-13 | 2020-03-17 | 不列颠哥伦比亚癌症局分支机构 | 用于癌症和其它疾病的医学成像的靶向缓激肽受体b1的组合物 |
GB201417067D0 (en) * | 2014-09-26 | 2014-11-12 | South African Nuclear Energy | Radiopharmaceutical conjugate |
JP2022513256A (ja) * | 2018-12-18 | 2022-02-07 | プロビンシャル・ヘルス・サービシーズ・オーソリティ | デュアルモード18f標識セラノスティック化合物及びその使用 |
-
2022
- 2022-05-26 WO PCT/US2022/031157 patent/WO2022251516A2/fr active Application Filing
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024155993A1 (fr) * | 2023-01-20 | 2024-07-25 | The Board Of Regents Of The University Of Texas System | Agents théranostiques ciblés pour l'imagerie et le traitement d'un cancer |
Also Published As
Publication number | Publication date |
---|---|
WO2022251516A3 (fr) | 2023-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220274974A1 (en) | Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer | |
KR102670305B1 (ko) | 알파-방출 방사선핵종의 거대고리형 복합체 및 암의 표적화된 방사선요법에서의 이의 용도 | |
Sprague et al. | Preparation and biological evaluation of copper-64–labeled Tyr3-octreotate using a cross-bridged macrocyclic chelator | |
CA2032499C (fr) | Derives de polypeptide | |
KR20190129931A (ko) | 영상화 및 항종양 치료요법에 유용한 조정 가능한 약동학을 갖는 삼작용성 작제물 | |
WO1996011954A1 (fr) | Analogues de somatostatine radiomarques tc ou re | |
IL201310A (en) | History of theoacetic acid and process for their preparation | |
US20100221240A1 (en) | Chemically Modified Peptide Analogs | |
JP2023524977A (ja) | 銅含有セラグノスティック化合物及びその使用の方法 | |
WO2022251516A2 (fr) | Complexes à chélateurs acycliques et leur utilisation en radiothérapie ciblée de cancer | |
JP2023510306A (ja) | 大環状キレートおよびその使用 | |
CA2199145C (fr) | Nouveaux ligands chelateurs de type n3s2 eventuellement radiomarques a l'aide de tc ou re et destines a etre utilises dans des applications diagnostiques ou therapeutiques | |
US20240261444A1 (en) | Rigidified macrocycles, complexes with radionuclides, and use in targeted radiotherapy of cancer | |
Dannoon et al. | In vitro structure–activity relationship of Re-cyclized octreotide analogues | |
EP1717247A1 (fr) | Peptides cycliques se liant au récepteur de somatostatin | |
WO2022251541A1 (fr) | Macrocycles et complexes avec des radionucléides utiles dans la radiothérapie ciblée du cancer | |
WO2000059896A1 (fr) | 225ac-heha et composes, procedes de synthese et procedes d'utilisation correspondants | |
WO2006114324A1 (fr) | Composes comprenant des peptides cyclises se liant aux recepteurs de la somatostatine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22812174 Country of ref document: EP Kind code of ref document: A2 |